updated the Lung Cancer PDF Loader for a better understanding of tables and context and added the new NCCN and IASLC Guidelines.

core/agent.py

@@ -139,10 +139,11 @@ Your primary purpose is to provide evidence-based clinical guidance on lung canc
 - Only after retrieving guideline information should you formulate your answer based on what was retrieved
 
 **STRICT QUERY ADHERENCE - ALL PROVIDERS REQUIREMENT:**
-- When the user explicitly requests information from "all guidelines", "all providers", "according to all guidelines", or similar phrasing, you MUST retrieve and present information from ALL available guideline providers (NCCN, ASCO, ESMO, NICE, Manus)
-- Do NOT selectively omit providers - if the user asks for "all", you must query each provider separately and include ALL results
+- When the user does **not** specify a particular guideline provider, you MUST interpret the question as "according to all guidelines" and base your answer on **all** available guideline providers (ASCO, ESMO, IASLC, NCCN, NICE).
+- When the user explicitly requests information from "all guidelines", "all providers", "according to all guidelines", or similar phrasing, you MUST retrieve and present information from ALL available guideline providers (ASCO, ESMO, IASLC, NCCN, NICE)
+- Do NOT selectively omit providers - if the user asks for "all" or does not name a specific provider, you must query each provider separately and include ALL results
 - Call the medical_guidelines_knowledge_tool multiple times (once per provider) when "all providers" is requested
-- Present a comprehensive answer that includes recommendations from every available provider
+- Present a comprehensive synthesized answer that clearly reflects the combined recommendations from all providers
 - If a specific provider has no information on the topic, explicitly state that in your response
 
 **TOOL USAGE REQUIREMENTS:**
@@ -165,13 +166,13 @@ Your primary purpose is to provide evidence-based clinical guidance on lung canc
   
   **PART 1: INLINE CITATIONS** - Add a citation immediately after EACH section or statement in your answer:
   * After each clinical statement, recommendation, or data point, add an inline citation in parentheses
-  * Format: (Source: [file name], Page: [page number], Provider: [provider])
-  * Example: "Local authorities must use coordinated campaigns to raise awareness (Source: NICE.pdf, Page: 6, Provider: NICE)."
+  * Format: (Source: [source name without file extension], Page: [page number], Provider: [provider])
+  * Example: "Local authorities must use coordinated campaigns to raise awareness (Source: NICE, Page: 6, Provider: NICE)."
   * If a section uses multiple pages, cite each: "Structure measures include... (Page: 6). Process measures include... (Page: 15). Outcome measures include... (Page: 8)."
   
   **PART 2: COMPREHENSIVE CITATION LIST AT END** - After your complete answer, add a section titled "**References**" that lists ALL pages cited:
-  * Format: (Source: [file name], Pages: [all page numbers in order], Provider: [provider name], Location: [specific sections/tables used])
-  * Example: (Source: NICE.pdf, Pages: 6, 8, 15, Provider: NICE, Location: Quality Statement 1 - Structure, Process, and Outcome measures)
+  * Format: (Source: [source name without file extension], Pages: [all page numbers in order], Provider: [provider name], Location: [specific sections/tables used])
+  * Example: (Source: NICE, Pages: 6, 8, 15, Provider: NICE, Location: Quality Statement 1 - Structure, Process, and Outcome measures)
   
 - **PAGE CITATION RULE - EXTREMELY IMPORTANT**: 
   * BEFORE writing your answer, review ALL retrieved pages (including context pages) and identify EVERY page that contains information you will use
@@ -180,7 +181,7 @@ Your primary purpose is to provide evidence-based clinical guidance on lung canc
   * At the end, list ALL unique page numbers in sequential order in the References section
   * Do NOT skip any pages - if you used information from a page, cite it inline AND in the final reference list
   * Context pages marked [CONTEXT PAGE] should be cited if they contributed to your answer
-- If a specific provider (NCCN, ASCO, ESMO, etc.) is mentioned in the question, prioritize information from that provider.
+- If a specific provider (ASCO, ESMO, IASLC, NCCN, NICE, etc.) is mentioned in the question, prioritize information from that provider.
 - When citing tables or flowcharts:
   * Specify the table/figure number and title
   * Describe which specific rows, columns, or sections contain the relevant information
@@ -197,7 +198,7 @@ Your primary purpose is to provide evidence-based clinical guidance on lung canc
   * Acknowledges the limitation: "I searched the available medical guidelines but could not find specific information about [topic]."
   * Suggests alternatives: "You may want to:
     - Rephrase your question with more specific clinical details
-    - Specify a particular guideline provider (NCCN, ASCO, ESMO, NICE)
+    - Specify a particular guideline provider (ASCO, ESMO, IASLC, NCCN, NICE)
     - Consult the latest published guidelines directly for emerging topics"
   * Maintains professionalism: Never simply say "I don't know" - always provide context and next steps
 - **NEVER answer from general knowledge or training data - ALWAYS use the tool first**
@@ -358,7 +359,7 @@ def _should_validate_response(user_input: str, response: str) -> bool:
     medical_indicators = [
         "treatment", "therapy", "diagnosis", "medication", "drug", "patient",
         "clinical", "guideline", "recommendation", "according to", "source:",
-        "provider:", "page:", "nccn", "asco", "esmo", "nice"
+        "provider:", "page:", "nccn", "asco", "esmo", "iaslc", "nice"
     ]
     
     return any(indicator in response_lower for indicator in medical_indicators)

core/data_loaders.py

@@ -66,7 +66,7 @@ def load_pdf_documents(pdf_path: Path) -> List[Document]:
                 processed_doc = Document(
                     page_content=doc.page_content,
                     metadata={
-                        "source": pdf_path.name,
+                        "source": pdf_path.stem,
                         "disease": disease,
                         "provider": provider,
                         "page_number": page_num
@@ -119,7 +119,7 @@ def load_markdown_documents(md_path: Path) -> List[Document]:
         doc = Document(
             page_content=content,
             metadata={
-                "source": md_path.name,
+                "source": md_path.stem,
                 "disease": disease,
                 "provider": provider,
                 "page_number": 1

core/tools.py

@@ -16,7 +16,7 @@ from .config import logger
 from langchain_openai import ChatOpenAI
 
 # Canonical provider names - used for "all providers" queries
-CANONICAL_PROVIDERS = ["NCCN", "ASCO", "ESMO", "NICE", "Manus"]
+CANONICAL_PROVIDERS = ["ASCO", "ESMO", "IASLC", "NCCN", "NICE"]
 
 # Global configuration for medical_guidelines_knowledge_tool retrieval and enrichment
 # These control the number of documents retrieved and context pages added
@@ -54,6 +54,10 @@ _PROVIDER_ALIASES = {
     "nice": "NICE",
     "national institute for health and care excellence": "NICE",
     "nice guidelines": "NICE",
+    # IASLC
+    "iaslc": "IASLC",
+    "international association for the study of lung cancer": "IASLC",
+    "iaslc guidelines": "IASLC",
     # Manus (custom provider)
     "manus": "Manus",
     "by manus": "Manus",
@@ -176,6 +180,8 @@ def _build_citation(index: int, metadata: dict, content: str, include_provider:
         Formatted citation string
     """
     source = metadata.get("source", "unknown")
+    if isinstance(source, str):
+        source = os.path.splitext(source)[0]
     page = metadata.get("page_number", "?")
     provider = metadata.get("provider", "unknown")
     disease = metadata.get("disease", "unknown")

data/chunks.pkl

@@ -1,3 +1,3 @@
 version https://git-lfs.github.com/spec/v1
-oid sha256:153fd4f385c2f5435400127bf59043d173d829ea0d933237cdba7784894e5c01
-size 3878666
+oid sha256:9fc8f7eab3b05dcbcbfa9bc91444910328a2e5158109b8ce3d26a99f57bb4da3
+size 5054054

data/medical_terms_cache.json

@@ -6,9 +6,9 @@
     "esmo": [
       "the european society for medical\noncology",
       "european society of medical oncology",
-      "the european society for medical oncology",
-      "european society for\nmedical oncology",
       "european society for medical oncology",
+      "european society for\nmedical oncology",
+      "the european society for medical oncology",
       "european\nsociety of medical oncology"
     ],
     "american society of clinical\n\noncology": [
@@ -16,10 +16,12 @@
     ],
     "asco": [
       "american society of clinical\n\noncology",
-      "inc",
-      "md american society of clinical oncology",
       "american society of clinical oncology",
-      "american\nsociety of clinical oncology"
+      "american\nsociety of clinical oncology",
+      "s note\n\nthis american society of clinical oncology",
+      "md american society of clinical oncology",
+      "journal of clinical oncology",
+      "inc"
     ],
     "italian association of medical oncology": [
       "aiom"
@@ -32,27 +34,30 @@
       "nccn"
     ],
     "nccn": [
-      "vs insurance-based",
       "national comprehensive cancer network",
-      "leading american cancer centers"
+      "leading american cancer centers",
+      "vs insurance-based"
     ],
     "non-small cell lung cancer": [
       "nsclc"
     ],
     "nsclc": [
-      "non-small cell lung cancer",
+      "e-mutant advanced non-small cell lung cancer",
+      "advanced non-small cell lung cancer",
+      "robotic lobectomy for non-small cell lung cancer",
+      "non-small-cell lung cancer",
+      "small cell lung cancer",
+      "mutant advanced non-small cell lung cancer",
       "advanced non-small-cell lung cancer",
+      "small-cell\nlung cancer",
       "small-cell lung cancer",
-      "small cell\nlung cancer",
       "iii non-small-cell lung cancer",
-      "mutant advanced non-small cell lung cancer",
-      "advanced non-small cell lung cancer",
       "stage iii non small cell lung cancer",
-      "small-cell\nlung cancer",
-      "cancer",
       "lung cancer",
-      "robotic lobectomy for non-small cell lung cancer",
-      "non-small-cell lung cancer"
+      "non-small cell lung cancer",
+      "cancer",
+      "small cell\nlung cancer",
+      "-rearranged advanced non-small-cell lung cancer"
     ],
     "american\nsociety of clinical oncology": [
       "asco"
@@ -70,25 +75,30 @@
       "glides"
     ],
     "glides": [
-      "using the guidelines into decision\nsupport",
-      "guidelines into decision support"
+      "guidelines into decision support",
+      "using the guidelines into decision support",
+      "using the guidelines into decision\nsupport"
     ],
     "for all the newly\neuropean medicines agency": [
       "ema"
     ],
     "ema": [
       "european medicines agency",
-      "for all the newly\neuropean medicines agency",
+      "and the european medicines agency",
       "and the european medicines\nagency",
-      "not european medicines agency"
+      "for all the newly\neuropean medicines agency",
+      "not european medicines agency",
+      "for all the newly european medicines agency"
     ],
     "evaluates treatments with curative intent": [
-      "such\nas adjuvant chemotherapy"
+      "such\nas adjuvant chemotherapy",
+      "such as adjuvant chemotherapy"
     ],
     "such\nas adjuvant chemotherapy": [
       "evaluates treatments with curative intent"
     ],
     "panel members": [
+      "from different institutions",
       "from\ndifferent institutions"
     ],
     "from\ndifferent institutions": [
@@ -104,7 +114,8 @@
       "magrit"
     ],
     "magrit": [
-      "-positive nonsmall-cell lung cancer"
+      "-positive nonsmall-cell lung cancer",
+      "-positive non-small-cell lung cancer"
     ],
     "guidelines into decision support": [
       "glides"
@@ -113,14 +124,17 @@
       "non-metastatic"
     ],
     "non-metastatic": [
+      "early-stage and locally advanced",
       "early-stage and\n\nlocally advanced"
     ],
     "or best supportive\ncare": [
       "bsc"
     ],
     "bsc": [
+      "or best supportive\ncare",
       "leads to\nincreased dfs versus best supportive care",
-      "or best supportive\ncare"
+      "or best supportive care",
+      "leads to increased dfs versus best supportive care"
     ],
     "author affiliations\nand support\n\ninformation": [
       "if\n\napplicable"
@@ -139,13 +153,15 @@
     ],
     "rcts": [
       "clinical trials",
-      "controlled trials",
-      "two randomized control trials"
+      "two randomized control trials",
+      "controlled trials"
     ],
     "the primary end point was disease-free\nsurvival": [
       "dfs"
     ],
     "dfs": [
+      "the primary end point was disease-free survival",
+      "disease-free survival",
       "the primary end point was disease-free\nsurvival"
     ],
     "joint cancer care ontario": [
@@ -161,72 +177,75 @@
       "inst"
     ],
     "inst": [
-      "bayer",
-      "pharmamar",
+      "crispr\ntherapeutics",
+      "merck",
       "trizell",
-      "macrogenics",
-      "blueprint medicines",
-      "astrazeneca",
-      "vivace therapeutics",
-      "bristol myers squibb",
-      "astrazeneca canada",
-      "black diamond\ntherapeutics",
-      "boehringer ingelheim",
       "anheart therapeutics",
-      "lilly",
-      "medimmune",
-      "bristol myers\nsquibb",
-      "exelixis",
-      "revolution medicines",
-      "jazz pharmaceuticals",
-      "pfizer",
-      "dizal\npharma",
-      "bristol myers squibb foundation",
-      "dohme",
-      "guardant health",
-      "oncomed",
-      "arcus biosciences",
-      "janssen",
-      "therapeutics",
-      "polaris",
-      "glaxosmithkline canada",
-      "calithera biosciences",
-      "nuvation bio",
-      "astex pharmaceuticals",
-      "advaxis",
+      "inc",
+      "regeneron",
+      "bms",
       "bristol-myers squibb",
-      "merck",
-      "summit therapeutics",
-      "turning point therapeutics",
+      "lilly",
+      "oric pharmaceuticals",
+      "elevation oncology",
       "amgen",
       "janssen oncology",
+      "verastem",
+      "medimmune",
+      "black diamond therapeutics",
+      "janssen",
+      "msd",
+      "guardant health",
       "palobiofarma",
+      "constellation pharmaceuticals",
       "neogenomics",
-      "crispr\ntherapeutics",
-      "inc",
-      "regeneron",
-      "forward",
-      "novartis",
+      "blueprint medicines",
+      "nuvation bio",
+      "pfizer",
+      "therapeutics",
+      "gsk",
+      "pharmamar",
       "mirati therapeutics",
-      "sutro biopharma",
-      "constellation pharmaceuticals",
-      "merck serono",
-      "puma biotechnology",
-      "msd",
-      "oric pharmaceuticals",
-      "genentech",
-      "takeda",
-      "abbvie",
-      "inhibrx",
       "glaxosmithkline",
-      "verastem",
+      "revolution medicines",
+      "dohme",
+      "crispr therapeutics",
+      "summit therapeutics",
       "harpoon therapeutics",
+      "macrogenics",
+      "jazz pharmaceuticals",
+      "glaxosmithkline canada",
+      "genentech",
+      "takeda",
       "astra zeneca",
       "cullinan oncology",
+      "abbvie",
+      "bristol myers\nsquibb",
+      "dizal\npharma",
+      "puma biotechnology",
+      "advaxis",
+      "novartis",
+      "vivace therapeutics",
+      "turning point therapeutics",
+      "astex pharmaceuticals",
+      "merck serono",
+      "oncomed",
+      "astrazeneca",
+      "exelixis",
+      "bayer",
+      "dizal pharma",
+      "inhibrx",
+      "calithera biosciences",
+      "polaris",
+      "arcus biosciences",
+      "astrazeneca canada",
+      "black diamond\ntherapeutics",
+      "boehringer ingelheim",
+      "sutro biopharma",
+      "bristol myers squibb",
+      "forward",
       "roche",
-      "gsk",
-      "bms",
-      "elevation oncology"
+      "bristol myers squibb foundation"
     ],
     "pfizer": [
       "inst"
@@ -235,6 +254,7 @@
       "inst"
     ],
     "bristol-myers squibb": [
+      "bms",
       "inst"
     ],
     "medimmune": [
@@ -244,24 +264,25 @@
       "limited stage"
     ],
     "limited stage": [
-      "of patients with\nstage i to iii sclc"
+      "of patients with\nstage i to iii sclc",
+      "of patients with stage i to iii sclc"
     ],
     "small-cell lung cancer": [
-      "pacific",
-      "nsclc"
+      "nsclc",
+      "pacific"
     ],
     "or small-cell lung cancer": [
       "sclc"
     ],
     "sclc": [
-      "or small-cell lung cancer",
+      "small cell lung cancer",
       "trial in small cell lung cancer",
-      "and small-cell lung cancer",
-      "small cell lung cancer"
+      "or small-cell lung cancer",
+      "and small-cell lung cancer"
     ],
     "cancer": [
-      "relay",
-      "nsclc"
+      "nsclc",
+      "relay"
     ],
     "and small-cell lung cancer": [
       "sclc"
@@ -283,16 +304,17 @@
       "continued"
     ],
     "continued": [
-      "all recommendations",
-      "the bottom line"
+      "medical guideline document - esmo open references",
+      "the bottom line",
+      "all recommendations"
     ],
     "salvage stereotactic body radiation therapy": [
       "sbrt"
     ],
     "sbrt": [
+      "salvage stereotactic body radiation therapy",
       "fdg-pet and stereotactic body radiotherapy",
       "sabr or stereotactic body radiotherapy",
-      "salvage stereotactic body radiation therapy",
       "stereotactic body radiotherapy"
     ],
     "oncomed": [
@@ -308,20 +330,23 @@
       "cap"
     ],
     "cap": [
+      "the college of american pathologists",
       "thecollege of americanpathologists"
     ],
     "association\nfor molecular pathology": [
       "amp"
     ],
     "amp": [
-      "association\nfor molecular pathology"
+      "association\nfor molecular pathology",
+      "association for molecular pathology"
     ],
     "and anaplastic lymphoma kinase": [
       "alk"
     ],
     "alk": [
-      "crizotinib-pretreated anaplastic lymphoma kinase",
+      "phoma kinase",
       "and anaplastic lymphoma kinase",
+      "crizotinib-pretreated anaplastic lymphoma kinase",
       "positive anaplastic lymphoma kinase"
     ],
     "immunohistochemistry": [
@@ -386,8 +411,8 @@
       "icis"
     ],
     "icis": [
-      "neoadjuvant immune checkpoint inhibitors",
-      "immune checkpoint inhibitors"
+      "immune checkpoint inhibitors",
+      "neoadjuvant immune checkpoint inhibitors"
     ],
     "american society of clinical oncology": [
       "asco"
@@ -408,12 +433,13 @@
       "inst"
     ],
     "bms": [
-      "bristol myers squibb",
-      "bristol-myers\nsquibb",
+      "bristol-myers squibb",
       "inst",
       "bristol myers\nsquibb",
+      "celgene",
       "bristol\nmyers squibb",
-      "celgene"
+      "bristol myers squibb",
+      "bristol-myers\nsquibb"
     ],
     "trizell": [
       "inst"
@@ -431,25 +457,31 @@
       "rct"
     ],
     "rct": [
-      "phase iib\nrandomised controlled trial",
-      "phase iii randomised clinical trial",
       "one randomized controlled trial",
-      "a phase iii randomised clinical trial"
+      "phase iib randomised controlled trial",
+      "phase iii randomised clinical trial",
+      "a phase iii randomised clinical trial",
+      "phase iib\nrandomised controlled trial"
     ],
     "the primary end point of progression-free survival": [
       "pfs"
     ],
     "pfs": [
-      "no\nimprovement in progression-free survival",
-      "and\nprogression-free survival",
       "the median progression-free\nsurvival",
-      "reported improved\nprogression-free survival",
-      "the median\nprogression-free survival",
+      "progression-free survival",
+      "and\nprogression-free survival",
+      "the median progression-free survival",
+      "and progression-free survival",
+      "no\nimprovement in progression-free survival",
       "quality of life and progression-free survival",
-      "the primary end point of progression-free survival"
+      "the median\nprogression-free survival",
+      "the primary end point of progression-free survival",
+      "reported improved\nprogression-free survival",
+      "reported improved progression-free survival"
     ],
     "adverse events": [
-      "aes"
+      "aes",
+      "all-cause"
     ],
     "aes": [
       "mainly altered lipid levels",
@@ -466,11 +498,13 @@
       "osimertinib"
     ],
     "osimertinib": [
-      "treatment is now an\negfr-targeted drug"
+      "treatment is now an\negfr-targeted drug",
+      "osi",
+      "treatment is now an egfr-targeted drug"
     ],
     "inc": [
-      "inst",
-      "asco"
+      "asco",
+      "inst"
     ],
     "small cell\nlung cancer": [
       "nsclc"
@@ -485,13 +519,15 @@
       "vegf"
     ],
     "vegf": [
+      "and vascular endothelial growth factor",
       "and vascular\nendothelial growth factor"
     ],
     "though rates of\nimmune-related aes": [
       "iraes"
     ],
     "iraes": [
-      "though rates of\nimmune-related aes"
+      "though rates of\nimmune-related aes",
+      "though rates of immune-related aes"
     ],
     "bristol myers squibb": [
       "bms",
@@ -501,8 +537,8 @@
       "inst"
     ],
     "dohme": [
-      "inst",
-      "msd"
+      "msd",
+      "inst"
     ],
     "mirati therapeutics": [
       "inst"
@@ -529,8 +565,8 @@
       "inst"
     ],
     "gsk": [
-      "inst",
-      "glaxosmithkline"
+      "glaxosmithkline",
+      "inst"
     ],
     "regeneron": [
       "inst"
@@ -560,7 +596,8 @@
       "and terminology"
     ],
     "nab-paclitaxel with or without bevacizumab": [
-      "in the absence of\ncontraindications to bevacizumab"
+      "in the absence of\ncontraindications to bevacizumab",
+      "in the absence of contraindications to bevacizumab"
     ],
     "in the absence of\ncontraindications to bevacizumab": [
       "nab-paclitaxel with or without bevacizumab"
@@ -587,8 +624,10 @@
       "health research methods"
     ],
     "health research methods": [
-      "va asco practice guidelines staff",
-      "va asco practice guideline staff"
+      "asco practice guidelines staff",
+      "va asco practice guideline staff",
+      "asco practice guideline staff",
+      "va asco practice guidelines staff"
     ],
     "in tyrosine kinase inhibitor": [
       "tki"
@@ -601,8 +640,10 @@
       "orr"
     ],
     "orr": [
+      "which had an overall response rate",
       "reuss et al\n\n\n\nrate",
-      "which had an overall response rate"
+      "- objective response rate",
+      "rate"
     ],
     "disease control rate": [
       "dcr"
@@ -620,8 +661,11 @@
       "dor"
     ],
     "dor": [
+      "the median\nduration of response",
+      "with a median duration of response",
       "with a median duration of\nresponse",
-      "the median\nduration of response"
+      "the median duration of response",
+      "- duration of response"
     ],
     "the most common treatment-emergent adverse events": [
       "teaes"
@@ -689,8 +733,9 @@
       "durvalumab"
     ],
     "durvalumab": [
-      "consolidation immunotherapy",
-      "if ps improves\n\nv\n\nconsolidation immunotherapy"
+      "if ps improves\n\nv\n\nconsolidation immunotherapy",
+      "if ps improves\n- consolidation immunotherapy",
+      "consolidation immunotherapy"
     ],
     "if ps improves\n\nv\n\nconsolidation immunotherapy": [
       "durvalumab"
@@ -705,14 +750,16 @@
       "bite"
     ],
     "bite": [
-      "a bispecific t-cell\nengager"
+      "a bispecific t-cell\nengager",
+      "a bispecific t-cell engager"
     ],
     "the most\ncommon ae was cytokine release syndrome": [
       "crs"
     ],
     "crs": [
       "the most\ncommon ae was cytokine release syndrome",
-      "cytokine release syndrome"
+      "cytokine release syndrome",
+      "the most common ae was cytokine release syndrome"
     ],
     "asco-ontario health": [
       "cancer care ontario"
@@ -736,13 +783,14 @@
       "fda"
     ],
     "fda": [
-      "the us food and drug administration",
-      "food and drug administration",
       "or food and drug administration",
-      "entrectinib received food and\ndrug administration",
       "the food and drug administration",
+      "entrectinib received food and\ndrug administration",
+      "entrectinib received food and drug administration",
+      "and the food and drug administration",
       "and the united states food and drug administration",
-      "and the food and drug administration"
+      "food and drug administration",
+      "the us food and drug administration"
     ],
     "cytokine release syndrome": [
       "crs"
@@ -751,7 +799,8 @@
       "icans"
     ],
     "icans": [
-      "associated neurotoxicity\nsyndrome"
+      "associated neurotoxicity\nsyndrome",
+      "associated neurotoxicity syndrome"
     ],
     "department of surgical sciences": [
       "ikv"
@@ -763,22 +812,26 @@
       "nets"
     ],
     "nets": [
+      "tumors",
       "has grouped lung and thymic neuroendocrine\ntumours",
-      "tumors"
+      "has grouped lung and thymic neuroendocrine tumours"
     ],
     "small cell lung cancer": [
+      "nsclc",
       "sclc"
     ],
     "and\nlarge cell neuroendocrine carcinoma": [
       "lcnec"
     ],
     "lcnec": [
-      "and\nlarge cell neuroendocrine carcinoma"
+      "and\nlarge cell neuroendocrine carcinoma",
+      "and large cell neuroendocrine carcinoma"
     ],
     "and thymic\ncarcinoid": [
       "thc"
     ],
     "thc": [
+      "and thymic carcinoid",
       "and thymic\ncarcinoid"
     ],
     "org": [
@@ -791,8 +844,8 @@
       "seer"
     ],
     "seer": [
-      "epidemiology and end results",
-      "and end results"
+      "and end results",
+      "epidemiology and end results"
     ],
     "s syndrome": [
       "cus"
@@ -810,7 +863,8 @@
       "ghrh"
     ],
     "ghrh": [
-      "due to\ngrowth hormone-releasing hormone"
+      "due to\ngrowth hormone-releasing hormone",
+      "due to growth hormone-releasing hormone"
     ],
     "contrast": [
       "liver mri"
@@ -835,7 +889,8 @@
     ],
     "ssas": [
       "-labelled somatostatin analogues",
-      "medical options"
+      "medical options",
+      "what is the role of somatostatin analogues"
     ],
     "urinary-free cortisol": [
       "ufc"
@@ -880,14 +935,18 @@
       "cht"
     ],
     "cht": [
-      "over platinum-based doublet\nchemotherapy",
-      "mainly cytotoxic chemotherapy",
       "chemotherapy",
-      "the beneficial effects of adjuvant chemotherapy",
       "the addition of the chemotherapy",
-      "platinum-based chemo\ntherapy"
+      "platinum-based chemotherapy",
+      "platinum-based chemo\ntherapy",
+      "over platinum-based doublet\nchemotherapy",
+      "over platinum-based doublet chemotherapy",
+      "with or without prior adjuvant chemotherapy",
+      "the beneficial effects of adjuvant chemotherapy",
+      "mainly cytotoxic chemotherapy"
     ],
     "or systemic therapies": [
+      "with options discussed in these guidelines",
       "with options\ndiscussed in these guidelines"
     ],
     "with options\ndiscussed in these guidelines": [
@@ -897,7 +956,8 @@
       "functioning syndrome"
     ],
     "functioning syndrome": [
-      "in case of\nclinical"
+      "in case of\nclinical",
+      "in case of clinical"
     ],
     "and the united states food and drug administration": [
       "fda"
@@ -906,14 +966,16 @@
       "pth"
     ],
     "pth": [
-      "annals of oncology\n\n\n\nparathyroid hormone"
+      "annals of oncology\n\n\n\nparathyroid hormone",
+      "parathyroid hormone"
     ],
     "palliative surgery\nor radiofrequency ablation": [
       "rfa"
     ],
     "rfa": [
-      "for these patients radiofrequency ablation",
-      "palliative surgery\nor radiofrequency ablation"
+      "palliative surgery\nor radiofrequency ablation",
+      "palliative surgery or radiofrequency ablation",
+      "for these patients radiofrequency ablation"
     ],
     "or cryoablation or endobronchial treatment": [
       "ebt"
@@ -925,7 +987,8 @@
       "prrt"
     ],
     "prrt": [
-      "peptide\nreceptor radionuclide therapy"
+      "peptide\nreceptor radionuclide therapy",
+      "peptide receptor radionuclide therapy"
     ],
     "and interferon- a": [
       "ifna"
@@ -973,15 +1036,18 @@
       "folfox"
     ],
     "folfox": [
+      "uorouracil",
       "-fluorouracil"
     ],
     "as alternative second-line": [
-      "in case of\nuncontrolled cs"
+      "in case of\nuncontrolled cs",
+      "in case of uncontrolled cs"
     ],
     "in case of\nuncontrolled cs": [
       "as alternative second-line"
     ],
     "or mainly third-line therapy": [
+      "beyond ssas and or everolimus",
       "beyond\nssas and or everolimus"
     ],
     "beyond\nssas and or everolimus": [
@@ -994,19 +1060,22 @@
       "ifn- a as a potential second-line"
     ],
     "or mainly third-line alternative": [
-      "beyond ssas and or\neverolimus"
+      "beyond ssas and or\neverolimus",
+      "beyond ssas and or everolimus"
     ],
     "beyond ssas and or\neverolimus": [
       "or mainly third-line alternative"
     ],
     "thymic net recurrences may be local": [
+      "if located in the anterior mediastinum",
       "if located in the\nanterior mediastinum"
     ],
     "if located in the\nanterior mediastinum": [
       "thymic net recurrences may be local"
     ],
     "regional": [
-      "intrathoracic especially\npleural"
+      "intrathoracic especially\npleural",
+      "intrathoracic especially pleural"
     ],
     "intrathoracic especially\npleural": [
       "regional"
@@ -1015,12 +1084,13 @@
       "esmo-mcbs"
     ],
     "esmo-mcbs": [
-      "an esmo\nmagnitude of clinical benefit scale",
-      "esmomagnitude of clinical benefit scale",
-      "esmo-magnitude of\nclinical benefit",
       "esmo-magnitude of clinical\nbenefit",
       "esmo-magnitude of clinical benefit scale",
-      "esmo-magnitude of clinical benefit"
+      "an esmo magnitude of clinical benefit scale",
+      "esmo-magnitude of\nclinical benefit",
+      "an esmo\nmagnitude of clinical benefit scale",
+      "esmo-magnitude of clinical benefit",
+      "esmomagnitude of clinical benefit scale"
     ],
     "advanced carcinoids of the lung and thymus": [
       "luna"
@@ -1074,8 +1144,8 @@
       "chuv"
     ],
     "chuv": [
-      "centre hospitalier universitaire\nvaudois",
-      "centre hospitalier universitaire vaudois"
+      "centre hospitalier universitaire vaudois",
+      "centre hospitalier universitaire\nvaudois"
     ],
     "comparing low-dose computed tomography": [
       "ldct"
@@ -1100,16 +1170,17 @@
       "eus"
     ],
     "eus": [
-      "or endoscopic\nultrasound"
+      "or endoscopic\nultrasound",
+      "or endoscopic ultrasound"
     ],
     "the recent world health organization": [
       "who"
     ],
     "who": [
-      "global",
-      "the recent world health organization",
       "world health organization",
       "global statistics",
+      "global",
+      "the recent world health organization",
       "vs universal"
     ],
     "with its further sub-classification of": [
@@ -1125,8 +1196,9 @@
       "ais"
     ],
     "ais": [
-      "proposed\nthat ais be classified as tis",
-      "the categories adenocarcinoma in situ"
+      "the categories adenocarcinoma in situ",
+      "proposed that ais be classified as tis",
+      "proposed\nthat ais be classified as tis"
     ],
     "minimally invasive adenocarcinoma": [
       "mia"
@@ -1147,7 +1219,8 @@
       "of fluorodeoxyglucose-positron emission tomography"
     ],
     "the rate of nos": [
-      "not otherwise\nspecified"
+      "not otherwise\nspecified",
+      "not otherwise specified"
     ],
     "not otherwise\nspecified": [
       "the rate of nos"
@@ -1156,15 +1229,17 @@
       "uicc"
     ],
     "uicc": [
+      "the union for international cancer control",
+      "the union for\ninternational cancer control",
       "union for international\ncancer control",
-      "union for international cancer control",
-      "the union for\ninternational cancer control"
+      "union for international cancer control"
     ],
     "node and metastasis": [
       "tnm"
     ],
     "tnm": [
       "tumourenodeemetastasis",
+      "tumour-node-metastasis",
       "node and metastasis"
     ],
     "proposed\nthat ais be classified as tis": [
@@ -1180,8 +1255,8 @@
       "sub"
     ],
     "sub": [
-      "a should be restricted to the same histological",
-      "research support as"
+      "research support as",
+      "a should be restricted to the same histological"
     ],
     "videoassisted mediastinoscopy": [
       "vam"
@@ -1193,8 +1268,9 @@
       "accp"
     ],
     "accp": [
-      "the\namerican college of chest physicians",
-      "whereas the american college of chest physicians"
+      "the american college of chest physicians",
+      "whereas the american college of chest physicians",
+      "the\namerican college of chest physicians"
     ],
     "adjuvant chemotherapy": [
       "radiotherapy"
@@ -1206,7 +1282,8 @@
       "vats"
     ],
     "vats": [
-      "or a video-assisted thoracoscopic surgery"
+      "or a video-assisted thoracoscopic surgery",
+      "video-assisted thoracic surgery"
     ],
     "based on the lung cancer study group": [
       "lcsg"
@@ -1224,6 +1301,7 @@
       "cabg or pci"
     ],
     "cabg or pci": [
+      "including",
       "acc guidelines\n\nneed for coronary\nintervention"
     ],
     "high risk surgery": [
@@ -1269,9 +1347,11 @@
       "neo"
     ],
     "neo": [
-      "the\nimmune strategy in the",
+      "resection and after",
+      "- immunotherapy is being studied in early nsclc as",
       "immunotherapy is being studied in early nsclc as",
-      "- immunotherapy is being studied in early nsclc as"
+      "the\nimmune strategy in the",
+      "the immune strategy in the"
     ],
     "cl\n\ntreatment of locally advanced stage": [
       "stage ill"
@@ -1305,7 +1385,8 @@
     ],
     "ests": [
       "and the european\nsociety of thoracic surgeons",
-      "and european society of thoracic surgeons"
+      "and european society of thoracic surgeons",
+      "and the european society of thoracic surgeons"
     ],
     "gv scagliotti": [
       "eds"
@@ -1317,8 +1398,8 @@
       "thoracoscore"
     ],
     "thoracoscore": [
-      "the thoracic surgery scoring\nsystem",
-      "the thoracic surgery scoring system"
+      "the thoracic surgery scoring system",
+      "the thoracic surgery scoring\nsystem"
     ],
     "stereotactic body radiotherapy": [
       "sbrt"
@@ -1327,8 +1408,8 @@
       "pulmonology"
     ],
     "pulmonology": [
-      "respiratory oncology",
-      "respiratory oncology unit"
+      "respiratory oncology unit",
+      "respiratory oncology"
     ],
     "edegem": [
       "antwerp"
@@ -1349,10 +1430,11 @@
       "stage iii"
     ],
     "stage iii": [
-      "locally advanced nsclc",
       "and unresectable locally advanced",
+      "unresectable nsclc",
       "treatment of locally advanced stage",
-      "unresectable nsclc"
+      "- locally advanced nsclc",
+      "locally advanced nsclc"
     ],
     "in paral\npractice guidelines": [
       "cpgs"
@@ -1365,6 +1447,7 @@
     ],
     "see panel members listed in the appendix": [
       "experts were involved in this\nconsensus process",
+      "experts were involved in this consensus process",
       "and a general consen\nconsensus process"
     ],
     "experts were involved in this\nconsensus process": [
@@ -1383,7 +1466,8 @@
       "as relative value depends on personal"
     ],
     "respiratory literature": [
-      "especially on exercise\ntesting"
+      "especially on exercise\ntesting",
+      "especially on exercise testing"
     ],
     "especially on exercise\ntesting": [
       "respiratory literature"
@@ -1407,14 +1491,15 @@
       "sub-lobar"
     ],
     "sub-lobar": [
-      "for which patients is limited",
-      "special articles\n\n\n\nfor which patients is limited"
+      "special articles\n\n\n\nfor which patients is limited",
+      "for which patients is limited"
     ],
     "especially those with ground-glass\nopacity": [
       "ggo"
     ],
     "ggo": [
-      "especially those with ground-glass\nopacity"
+      "especially those with ground-glass\nopacity",
+      "especially those with ground-glass opacity"
     ],
     "special articles\n\n\n\nfor which patients is limited": [
       "sub-lobar"
@@ -1423,8 +1508,9 @@
       "sabr"
     ],
     "sabr": [
-      "other approaches such as local ablative",
-      "solidative stereotactic ablative radiotherapy"
+      "solidative stereotactic ablative radiotherapy",
+      "consolidative stereotactic ablative radiotherapy",
+      "other approaches such as local ablative"
     ],
     "some trials": [
       "ialt"
@@ -1451,8 +1537,9 @@
       "prevalence"
     ],
     "prevalence": [
-      "results of\nthe initial",
-      "results of the\ninitial"
+      "results of the\ninitial",
+      "results of the initial",
+      "results of\nthe initial"
     ],
     "results of the\ninitial": [
       "prevalence"
@@ -1461,7 +1548,8 @@
       "prevalance"
     ],
     "prevalance": [
-      "results\nof the initial"
+      "results\nof the initial",
+      "results of the initial"
     ],
     "the thoracic surgery scoring system": [
       "thoracoscore"
@@ -1479,8 +1567,9 @@
       "vumc"
     ],
     "vumc": [
+      "vrije\nuniversity medical centre",
       "university medical centre",
-      "vrije\nuniversity medical centre"
+      "vrije university medical centre"
     ],
     "university medical centre": [
       "vumc"
@@ -1492,8 +1581,9 @@
       "pbc"
     ],
     "pbc": [
-      "platinum-based doublet chemotherapy",
-      "five cycles of\n\ntremelimumab"
+      "five cycles of tremelimumab",
+      "five cycles of\n\ntremelimumab",
+      "platinum-based doublet chemotherapy"
     ],
     "carboplatin": [
       "arm b",
@@ -1506,7 +1596,8 @@
       "carboplatin"
     ],
     "pbc significantly improved pfs": [
-      "primary\nendpoint"
+      "primary\nendpoint",
+      "primary endpoint"
     ],
     "primary\nendpoint": [
       "pbc significantly improved pfs"
@@ -1517,15 +1608,17 @@
     "primary endpoint": [
       "pbc\nsignificantly improved pfs",
       "significantly improved os",
-      "-year os",
-      "level"
+      "pbc significantly improved pfs",
+      "level",
+      "-year os"
     ],
     "besides immune checkpoint\n\ninhibitor": [
       "ici"
     ],
     "ici": [
-      "and have no prior immune checkpoint inhibitor",
-      "besides immune checkpoint\n\ninhibitor"
+      "besides immune checkpoint inhibitor",
+      "besides immune checkpoint\n\ninhibitor",
+      "and have no prior immune checkpoint inhibitor"
     ],
     "esmo-magnitude of clinical benefit scale": [
       "mcbs",
@@ -1559,6 +1652,7 @@
       "ttfields"
     ],
     "ttfields": [
+      "tumour treating fields",
       "tumour treating\nfields"
     ],
     "significantly improved os": [
@@ -1569,9 +1663,12 @@
     ],
     "esmo guidelines staff": [
       "ioanna ntai and claire bramley",
-      "jennifer\nlamarre and guy atchison"
+      "jennifer lamarre and guy atchison",
+      "jennifer\nlamarre and guy atchison",
+      "valerie laforest"
     ],
     "valerie laforest": [
+      "esmo guidelines staff",
       "esmo\nguidelines staff"
     ],
     "esmo\nguidelines staff": [
@@ -1581,10 +1678,11 @@
       "esmo scientific affairs staff"
     ],
     "esmo scientific affairs staff": [
+      "nicola latino and francesca chiovaro",
       "nicola latino and\nfrancesca chiovaro",
+      "nicola latino",
       "nicola\nlatino and francesca chiovaro",
-      "nicola\nlatino",
-      "nicola latino"
+      "nicola\nlatino"
     ],
     "bristol\nmyers squibb": [
       "bms"
@@ -1602,7 +1700,8 @@
       "ipsos"
     ],
     "ipsos": [
-      "with a platinum-containing\nregimen"
+      "with a platinum-containing\nregimen",
+      "roche and                                regimen"
     ],
     "esmo clinical practice guideline": [
       "cpg"
@@ -1634,13 +1733,16 @@
       "ntrk"
     ],
     "ntrk": [
-      "and the neurotrophic receptor tyrosine\nkinase",
-      "or neurotrophic tyrosine\nreceptor kinase"
+      "- the neurotrophic receptor tyrosine kinase",
+      "or neurotrophic tyrosine receptor kinase",
+      "or neurotrophic tyrosine\nreceptor kinase",
+      "and the neurotrophic receptor tyrosine\nkinase"
     ],
     "detection is reliable by\nin situ hybridisation": [
       "ish"
     ],
     "ish": [
+      "detection is reliable by in situ hybridisation",
       "detection is reliable by\nin situ hybridisation"
     ],
     "mesenchymal-epithelial transition": [
@@ -1653,8 +1755,9 @@
       "cfdna"
     ],
     "cfdna": [
-      "cell-free dna",
-      "liquid biopsy"
+      "what is the role of liquid biopsy",
+      "liquid biopsy",
+      "cell-free dna"
     ],
     "multiplex platforms": [
       "ngs"
@@ -1678,7 +1781,8 @@
       "fdg"
     ],
     "fdg": [
-      "e\ndeoxy-d-glucose"
+      "e\ndeoxy-d-glucose",
+      "-deoxy-d-glucose"
     ],
     "union for international\ncancer control": [
       "uicc"
@@ -1700,15 +1804,17 @@
       "mpfs"
     ],
     "mpfs": [
-      "demonstrating a superior\nmedian pfs"
+      "demonstrating a superior\nmedian pfs",
+      "demonstrating a superior median pfs"
     ],
     "and median os": [
       "mos"
     ],
     "mos": [
+      "and median os",
+      "malaysian oncological society",
       "malaysia",
-      "the malaysian oncological society",
-      "and median os"
+      "the malaysian oncological society"
     ],
     "systemic progression\n\nlocal treatment": [
       "surgery or ft"
@@ -1742,14 +1848,15 @@
       "japan"
     ],
     "japan": [
-      "j-alex",
-      "jsmo"
+      "jsmo",
+      "j-alex"
     ],
     "and\nalesia": [
       "asia"
     ],
     "asia": [
-      "and\nalesia"
+      "and\nalesia",
+      "and alesia"
     ],
     "and continue targeted": [
       "not mandatory for decision"
@@ -1782,7 +1889,8 @@
       "mdor"
     ],
     "mdor": [
-      "the\nmedian duration of response"
+      "the\nmedian duration of response",
+      "the median duration of response"
     ],
     "tropomyosin receptor tyrosine kinase": [
       "trk"
@@ -1794,8 +1902,9 @@
       "surgery or rt"
     ],
     "surgery or rt": [
-      "local treatment",
       "oligoprogression\n\nlocal treatment",
+      "local treatment",
+      "- local treatment",
       "disease progression\n\nlocal treatment"
     ],
     "or combination therapy with a mek inhibitor": [
@@ -1823,6 +1932,7 @@
       "kras"
     ],
     "kras": [
+      "the kirsten rat sarcoma virus",
       "the\nkirsten rat sarcoma virus"
     ],
     "data regarding the role of local ablative therapy": [
@@ -1841,6 +1951,7 @@
       "robotic systems"
     ],
     "robotic systems": [
+      "in particular with the use of modern technologies",
       "in particular with the use\nof modern technologies"
     ],
     "esmo-magnitude of\nclinical benefit": [
@@ -1850,8 +1961,9 @@
       "high-dose rt or surgery"
     ],
     "high-dose rt or surgery": [
-      "may\nbenefit from lat",
-      "from lat"
+      "may benefit from lat",
+      "from lat",
+      "may\nbenefit from lat"
     ],
     "jennifer\nlamarre and guy atchison": [
       "esmo guidelines staff"
@@ -1860,8 +1972,9 @@
       "esmo scientific affairs staff"
     ],
     "and dr svetlana jezdic": [
-      "esmo medical affairs staff",
-      "esmo\nmedical affairs advisor"
+      "esmo\nmedical affairs advisor",
+      "esmo medical affairs advisor",
+      "esmo medical affairs staff"
     ],
     "esmo\nmedical affairs advisor": [
       "and dr svetlana jezdic"
@@ -1873,13 +1986,15 @@
       "atorg"
     ],
     "atorg": [
-      "asian\nthoracic oncology research group"
+      "asian\nthoracic oncology research group",
+      "asian thoracic oncology research group"
     ],
     "chinese lung\ncancer research foundation limited": [
       "clcrf"
     ],
     "clcrf": [
-      "chinese lung\ncancer research foundation limited"
+      "chinese lung\ncancer research foundation limited",
+      "chinese lung cancer research foundation limited"
     ],
     "chinese society of clinical oncology": [
       "csco"
@@ -1927,7 +2042,8 @@
       "rtp"
     ],
     "rtp": [
-      "research\nto practice"
+      "research\nto practice",
+      "research to practice"
     ],
     "research": [
       "ukcccr",
@@ -1946,7 +2062,8 @@
       "asmac"
     ],
     "asmac": [
-      "s\nde clinique"
+      "s\nde clinique",
+      "s de clinique"
     ],
     "rzte": [
       "vsao"
@@ -1967,6 +2084,7 @@
       "cancers"
     ],
     "relay": [
+      "advanced non-small-cell lung cancer",
       "cancer"
     ],
     "non-small-cell lung cancer": [
@@ -1980,7 +2098,8 @@
       "alk"
     ],
     "advanced non-small-cell lung cancer": [
-      "nsclc"
+      "nsclc",
+      "relay"
     ],
     "fda prescribing information - rozlytrek": [
       "entrectinib"
@@ -1992,9 +2111,9 @@
       "chmp"
     ],
     "chmp": [
+      "tabrecta - summary of opinion",
       "products for human use",
-      "retsevmo - summary of opinion",
-      "tabrecta - summary of opinion"
+      "retsevmo - summary of opinion"
     ],
     "tabrecta - summary of opinion": [
       "chmp"
@@ -2031,6 +2150,7 @@
     ],
     "jsmo": [
       "the\njapanese society of medical oncology",
+      "the japanese society of medical oncology",
       "japan"
     ],
     "korea": [
@@ -2046,16 +2166,19 @@
       "psmo"
     ],
     "psmo": [
+      "the philippine society of medical oncology",
+      "and philippine society of medical oncology",
+      "the philippines",
       "and philippine society of medical\noncology",
-      "the philippine society of\nmedical oncology",
-      "the philippines"
+      "the philippine society of\nmedical oncology"
     ],
     "singapore": [
       "sso"
     ],
     "sso": [
-      "singapore",
-      "the singapore society of\noncology"
+      "the singapore society of oncology",
+      "the singapore society of\noncology",
+      "singapore"
     ],
     "taiwan": [
       "tos"
@@ -2069,7 +2192,8 @@
     ],
     "tsco": [
       "and thailand",
-      "and the\nthai society of clinical oncology"
+      "and the\nthai society of clinical oncology",
+      "and the thai society of clinical oncology"
     ],
     "and the neurotrophic receptor tyrosine\nkinase": [
       "ntrk"
@@ -2105,6 +2229,7 @@
       "tmk and hrk"
     ],
     "tmk and hrk": [
+      "only two of the six expert members from the ksmo",
       "only two of the six\nexpert members from the ksmo"
     ],
     "performance status": [
@@ -2130,8 +2255,9 @@
       "pet"
     ],
     "pet": [
-      "of whom had undergone positron\nemission tomography",
-      "-positron emission topography"
+      "-positron emission topography",
+      "had undergone positron emission tomography",
+      "of whom had undergone positron\nemission tomography"
     ],
     "union for international cancer control": [
       "uicc"
@@ -2180,7 +2306,9 @@
       "traes"
     ],
     "traes": [
-      "treatment-related aes"
+      "treatment-related aes",
+      "what are the treatment-related adverse events",
+      "treatment-related adverse events"
     ],
     "and have no prior immune checkpoint inhibitor": [
       "ici"
@@ -2198,6 +2326,7 @@
       "jkn"
     ],
     "jkn": [
+      "ishmo\n\nthe jaminan kesehatan nasional",
       "ishmo\n\n\nthe jaminan kesehatan nasional"
     ],
     "there is no regulation of partial coverage": [
@@ -2210,6 +2339,7 @@
       "pap"
     ],
     "pap": [
+      "program",
       "esmo open\n\n\n\nprogram"
     ],
     "mandatory national health insurance": [
@@ -2228,6 +2358,7 @@
       "csmbs"
     ],
     "csmbs": [
+      "social security and government officer",
       "social\nsecurity and government officer"
     ],
     "alk inhibitors": [
@@ -2237,13 +2368,15 @@
       "alk inhibitors"
     ],
     "and atezolizumab": [
+      "in the second-line setting",
       "in the\nsecond-line setting"
     ],
     "in the\nsecond-line setting": [
       "and atezolizumab"
     ],
     "erlotinib and osimertinib": [
-      "second-line with reimbursement\nthrough the csmbs"
+      "second-line with reimbursement\nthrough the csmbs",
+      "second-line with reimbursement through the csmbs"
     ],
     "second-line with reimbursement\nthrough the csmbs": [
       "erlotinib and osimertinib"
@@ -2252,7 +2385,8 @@
       "first-line"
     ],
     "first-line": [
-      "and the alk inhibitors ceritinib and\nbrigatinib"
+      "and the alk inhibitors ceritinib and\nbrigatinib",
+      "and the alk inhibitors ceritinib and brigatinib"
     ],
     "german": [
       "merck"
@@ -2261,6 +2395,7 @@
       "torg"
     ],
     "torg": [
+      "thoracic oncology research group",
       "thoracic oncology research\ngroup"
     ],
     "and west japan oncology group": [
@@ -2270,6 +2405,7 @@
       "and west japan oncology group"
     ],
     "product samples": [
+      "non-renumerated",
       "nonrenumerated"
     ],
     "nonrenumerated": [
@@ -2322,14 +2458,16 @@
       "osi"
     ],
     "osi": [
-      "mertinib"
+      "mertinib",
+      "osimertinib"
     ],
     "platinum-pemetrexed in egfr-mutated": [
       "egfrm"
     ],
     "egfrm": [
-      "with stage ibeiiia egfr mutation positive",
-      "platinum-pemetrexed in egfr-mutated"
+      "with stage ib-iiia egfr mutation positive",
+      "platinum-pemetrexed in egfr-mutated",
+      "with stage ibeiiia egfr mutation positive"
     ],
     "advanced non-small cell lung cancer": [
       "nsclc"
@@ -2341,18 +2479,21 @@
       "mnsclc"
     ],
     "mnsclc": [
+      "stage iv metastatic non-small-cell lung cancer",
       "e-mutant metastatic nsclc"
     ],
     "binimetinib in patients": [
       "pts"
     ],
     "pts": [
-      "p repotrectinib in patients",
       "versus docetaxel in patients",
       "patients",
-      "binimetinib in patients",
       "therapy in patients",
-      "mo encorafenib plus\n\nbinimetinib in patients"
+      "mo encorafenib plus\n\nbinimetinib in patients",
+      "p repotrectinib in patients",
+      "mo encorafenib plus binimetinib in patients",
+      "binimetinib in patients",
+      "osimertinib as adjuvant therapy in patients"
     ],
     "mutant advanced non-small cell lung cancer": [
       "nsclc"
@@ -2368,6 +2509,7 @@
     ],
     "treatment of early stages": [
       "stages i-ii",
+      "stages i and ii",
       "stages i-iiia"
     ],
     "stages i-iiia": [
@@ -2380,6 +2522,7 @@
       "ema"
     ],
     "chemotherapy": [
+      "- everolimus\n   - cht",
       "adaura",
       "cht"
     ],
@@ -2387,6 +2530,7 @@
       "ne-ne"
     ],
     "ne-ne": [
+      "the median was not reached",
       "the median\nwas not reached"
     ],
     "neoadjuvant immune checkpoint inhibitors": [
@@ -2399,7 +2543,8 @@
       "neo"
     ],
     "or docetaxel or pemetrexed": [
-      "only in\nadenocarcinoma tumours"
+      "only in\nadenocarcinoma tumours",
+      "only in adenocarcinoma tumours"
     ],
     "only in\nadenocarcinoma tumours": [
       "or docetaxel or pemetrexed"
@@ -2408,7 +2553,9 @@
       "port"
     ],
     "port": [
-      "post-operative radiotherapy"
+      "comparing post-operative conformal radiotherapy",
+      "post-operative radiotherapy",
+      "postoperative radiotherapy"
     ],
     "treatment of locally advanced stage": [
       "stage iii"
@@ -2447,8 +2594,9 @@
       "pacific"
     ],
     "pacific": [
+      "small-cell lung cancer",
       "concurrent chemoradiation therapy",
-      "small-cell lung cancer"
+      "unresectable non-small-cell lung cancer"
     ],
     "adaura": [
       "chemotherapy"
@@ -2457,10 +2605,12 @@
       "including stage ib"
     ],
     "including stage ib": [
+      "approval was based on all patient data",
       "d approval was based on all patient data"
     ],
     "on tumour cells": [
-      "as per the\nema-approved indication"
+      "as per the\nema-approved indication",
+      "as per the ema-approved indication"
     ],
     "as per the\nema-approved indication": [
       "on tumour cells"
@@ -2509,14 +2659,16 @@
       "chemo"
     ],
     "chemo": [
-      "platinum-based chemotherapy",
-      "platinum-doublet\nchemotherapy"
+      "platinum-doublet chemotherapy",
+      "platinum-doublet\nchemotherapy",
+      "platinum-based chemotherapy"
     ],
     "for\nresectable": [
       "ib-iiia"
     ],
     "ib-iiia": [
-      "for\nresectable"
+      "for\nresectable",
+      "for resectable"
     ],
     "lung cancer": [
       "nsclc"
@@ -2540,6 +2692,7 @@
       "diques august pi i sunyer"
     ],
     "department of radiation oncology": [
+      "maastro",
       "maastro clinic"
     ],
     "maastro clinic": [
@@ -2706,7 +2859,8 @@
       "pts"
     ],
     "platinum-based chemotherapy": [
-      "chemo"
+      "chemo",
+      "cht"
     ],
     "bristol myers squibb statement on opdivo": [
       "nivolumab"
@@ -2793,8 +2947,8 @@
       "esmo"
     ],
     "nice": [
-      "nhs",
-      "national institute for health and care excellence"
+      "national institute for health and care excellence",
+      "nhs"
     ],
     "national institute for health and care excellence": [
       "nice"
@@ -2867,122 +3021,769 @@
     ],
     "global statistics": [
       "who"
-    ]
-  },
-  "abbreviations": {
-    "esmo": [
-      "the following european society for medical oncology",
-      "the most recent european society for medical oncology",
-      "european society of medical oncology",
-      "the european society for medical oncology",
-      "european society for medical\noncology",
-      "european society for medical oncology",
-      "european society for\nmedical oncology",
-      "european\nsociety of medical oncology"
     ],
-    "asco": [
-      "this american society of clinical oncology",
-      "american society of clinical\n\noncology",
-      "the clinical practice guidelines published herein are provided by the american society of clinical oncology inc",
-      "american society of clinical oncology",
-      "american society of clinical\noncology",
-      "american\nsociety of clinical oncology"
+    "using the guidelines into decision support": [
+      "glides"
     ],
-    "aiom": [
-      "the italian association of medical oncology",
-      "italian association\nof medical oncology",
-      "italian association of medical oncology"
+    "for all the newly european medicines agency": [
+      "ema"
     ],
-    "nccn": [
-      "national comprehensive cancer network",
-      "american cancer centers"
+    "such as adjuvant chemotherapy": [
+      "evaluates treatments with curative intent"
     ],
-    "glides": [
-      "guidelines into decision\nsupport",
-      "ecision support"
+    "from different institutions": [
+      "panel members"
     ],
-    "glc": [
-      "guidelines committee"
+    "and the early study interruption": [
+      "even if based on pre-specified interim analysis"
     ],
-    "mcbs": [
-      "magnitude of clinical benefit scale",
-      "magnitude\nof clinical benefit score"
+    "even if based on pre-specified interim analysis": [
+      "and the early study interruption"
     ],
-    "ema": [
-      "european medicines agency",
-      "european medicines\nagency"
+    "-positive non-small-cell lung cancer": [
+      "magrit"
     ],
-    "sclc": [
-      "clinical practice guidelines on small cell lung\ncancer",
-      "small cell lung cancer"
+    "early-stage and locally advanced": [
+      "non-metastatic"
     ],
-    "cco": [
-      "cancer care ontario"
+    "the primary end point was disease-free survival": [
+      "dfs"
     ],
-    "astro": [
-      "executive summary of an american society for\nradiation oncology"
+    "or best supportive care": [
+      "bsc"
     ],
-    "inst": [
-      "bayer",
-      "trizell",
-      "macrogenics",
-      "blueprint medicines",
-      "bristol myers squibb",
-      "vivace therapeutics",
-      "zeneca canada",
-      "black diamond\ntherapeutics",
-      "boehringer ingelheim",
-      "lilly",
-      "bristol myers\nsquibb",
-      "exelixis",
-      "revolution medicines",
-      "jazz pharmaceuticals",
-      "pfizer",
-      "dizal\npharma",
-      "bristol myers squibb foundation",
-      "dohme",
-      "guardant health",
-      "arcus biosciences",
-      "janssen",
-      "therapeutics",
-      "polaris",
-      "zeneca",
-      "myers squibb",
-      "calithera biosciences",
-      "nuvation bio",
-      "astex pharmaceuticals",
-      "advaxis",
-      "pharmaceuticals",
+    "of patients with stage i to iii sclc": [
+      "limited stage"
+    ],
+    "the college of american pathologists": [
+      "cap"
+    ],
+    "association for molecular pathology": [
+      "amp"
+    ],
+    "newly diagnosed nonepithelioid mesothelioma": [
+      "biphasic or sarcomatoid"
+    ],
+    "biphasic or sarcomatoid": [
+      "newly diagnosed nonepithelioid mesothelioma"
+    ],
+    "crispr therapeutics": [
+      "inst"
+    ],
+    "pemetrexed": [
+      "non squamous only"
+    ],
+    "non squamous only": [
+      "pemetrexed"
+    ],
+    "all other patients": [
+      "without egfr mutations"
+    ],
+    "without egfr mutations": [
+      "all other patients"
+    ],
+    "treatment is now an egfr-targeted drug": [
+      "osimertinib"
+    ],
+    "s note\n\nthis american society of clinical oncology": [
+      "asco"
+    ],
+    "the median progression-free survival": [
+      "pfs"
+    ],
+    "and vascular endothelial growth factor": [
+      "vegf"
+    ],
+    "though rates of immune-related aes": [
+      "iraes"
+    ],
+    "black diamond therapeutics": [
+      "inst"
+    ],
+    "in the absence of contraindications to bevacizumab": [
+      "nab-paclitaxel with or without bevacizumab"
+    ],
+    "squamous cell carcinoma": [
+      "scc"
+    ],
+    "scc": [
+      "squamous cell carcinoma"
+    ],
+    "asco practice guideline staff": [
+      "health research methods"
+    ],
+    "tumor proportion score": [
+      "tps"
+    ],
+    "tps": [
+      "tumor proportion score"
+    ],
+    "rate": [
+      "orr"
+    ],
+    "with a median duration of response": [
+      "dor"
+    ],
+    "journal of clinical oncology": [
+      "asco"
+    ],
+    "dizal pharma": [
+      "inst"
+    ],
+    "weak": [
+      "continued on following page"
+    ],
+    "continued on following page": [
+      "weak"
+    ],
+    "asco practice guidelines staff": [
+      "health research methods"
+    ],
+    "infusion-related reactions": [
+      "composite term"
+    ],
+    "composite term": [
+      "infusion-related reactions"
+    ],
+    "limited-stage sclc": [
+      "ls-sclc"
+    ],
+    "ls-sclc": [
+      "limited-stage sclc"
+    ],
+    "if ps improves\n- consolidation immunotherapy": [
+      "durvalumab"
+    ],
+    "extensive-stage sclc": [
+      "es-sclc"
+    ],
+    "es-sclc": [
+      "extensive-stage sclc"
+    ],
+    "a bispecific t-cell engager": [
+      "bite"
+    ],
+    "the most common ae was cytokine release syndrome": [
+      "crs"
+    ],
+    "and progression-free survival": [
+      "pfs"
+    ],
+    "progression-free survival": [
+      "pfs"
+    ],
+    "all-cause": [
+      "adverse events"
+    ],
+    "immune-related aes": [
+      "any grade"
+    ],
+    "any grade": [
+      "immune-related aes"
+    ],
+    "associated neurotoxicity syndrome": [
+      "icans"
+    ],
+    "has grouped lung and thymic neuroendocrine tumours": [
+      "nets"
+    ],
+    "and large cell neuroendocrine carcinoma": [
+      "lcnec"
+    ],
+    "and thymic carcinoid": [
+      "thc"
+    ],
+    "due to growth hormone-releasing hormone": [
+      "ghrh"
+    ],
+    "surgery represents the treatment of choice for lcs": [
+      "both tcs and acs"
+    ],
+    "both tcs and acs": [
+      "surgery represents the treatment of choice for lcs"
+    ],
+    "with options discussed in these guidelines": [
+      "or systemic therapies"
+    ],
+    "in case of clinical": [
+      "functioning syndrome"
+    ],
+    "parathyroid hormone": [
+      "pth"
+    ],
+    "palliative surgery or radiofrequency ablation": [
+      "rfa"
+    ],
+    "peptide receptor radionuclide therapy": [
+      "prrt",
+      "- prrt"
+    ],
+    "what is the role of somatostatin analogues": [
+      "ssas"
+    ],
+    "uorouracil": [
+      "folfox"
+    ],
+    "in case of uncontrolled cs": [
+      "as a potential second-line",
+      "as alternative second-line"
+    ],
+    "beyond ssas and or everolimus": [
+      "or mainly third-line alternative",
+      "or mainly third-line therapy"
+    ],
+    "as a potential second-line": [
+      "in case of uncontrolled cs"
+    ],
+    "if located in the anterior mediastinum": [
+      "thymic net recurrences may be local"
+    ],
+    "intrathoracic especially pleural": [
+      "regional"
+    ],
+    "an esmo magnitude of clinical benefit scale": [
+      "esmo-mcbs"
+    ],
+    "results from the randomized phase iii study": [
+      "sanet-ep"
+    ],
+    "sanet-ep": [
+      "results from the randomized phase iii study"
+    ],
+    "- ssas": [
+      "somatostatin analogues"
+    ],
+    "somatostatin analogues": [
+      "- ssas"
+    ],
+    "- prrt": [
+      "peptide receptor radionuclide therapy"
+    ],
+    "- everolimus\n   - cht": [
+      "chemotherapy"
+    ],
+    "in patients with refractory cs": [
+      "carcinoid syndrome"
+    ],
+    "carcinoid syndrome": [
+      "in patients with refractory cs"
+    ],
+    "due to the lack of specific lc": [
+      "lung carcinoid"
+    ],
+    "lung carcinoid": [
+      "due to the lack of specific lc"
+    ],
+    "the flowchart is divided into sections for tc": [
+      "typical carcinoid"
+    ],
+    "typical carcinoid": [
+      "the flowchart is divided into sections for tc"
+    ],
+    "and thc": [
+      "thymic carcinoid"
+    ],
+    "thymic carcinoid": [
+      "and thc"
+    ],
+    "or endoscopic ultrasound": [
+      "eus"
+    ],
+    "not otherwise specified": [
+      "the rate of nos"
+    ],
+    "the union for international cancer control": [
+      "uicc"
+    ],
+    "proposed that ais be classified as tis": [
+      "ais"
+    ],
+    "and peripheral tumour": [
+      "outer third of the lung"
+    ],
+    "outer third of the lung": [
+      "and peripheral tumour"
+    ],
+    "current complaint of chest pain": [
+      "myocardial ischaemia"
+    ],
+    "myocardial ischaemia": [
+      "current complaint of chest pain"
+    ],
+    "stages i and ii": [
+      "treatment of early stages"
+    ],
+    "including": [
+      "cabg or pci"
+    ],
+    "undergo platinum-based cht": [
+      "preferably cisplatin"
+    ],
+    "preferably cisplatin": [
+      "undergo platinum-based cht"
+    ],
+    "phoma kinase": [
+      "alk"
+    ],
+    "and the european society of thoracic surgeons": [
+      "ests"
+    ],
+    "experts were involved in this consensus process": [
+      "see panel members listed in the appendix"
+    ],
+    "- locally advanced nsclc": [
+      "stage iii"
+    ],
+    "the american college of chest physicians": [
+      "accp"
+    ],
+    "especially on exercise testing": [
+      "respiratory literature"
+    ],
+    "especially those with ground-glass opacity": [
+      "ggo"
+    ],
+    "results of the initial": [
+      "prevalance",
+      "prevalence"
+    ],
+    "video-assisted thoracic surgery": [
+      "vats"
+    ],
+    "vrije university medical centre": [
+      "vumc"
+    ],
+    "besides immune checkpoint inhibitor": [
+      "ici"
+    ],
+    "five cycles of tremelimumab": [
+      "pbc"
+    ],
+    "tumour treating fields": [
+      "ttfields"
+    ],
+    "maastro": [
+      "department of radiation oncology"
+    ],
+    "nicola latino and francesca chiovaro": [
+      "esmo scientific affairs staff"
+    ],
+    "oncology group": [
+      "chair of the steering committee"
+    ],
+    "chair of the steering committee": [
+      "oncology group"
+    ],
+    "roche and                                regimen": [
+      "ipsos"
+    ],
+    "sion on or after            platinum-based therapy": [
+      "lunar"
+    ],
+    "lunar": [
+      "sion on or after            platinum-based therapy"
+    ],
+    "fusions": [
+      "rearrangements"
+    ],
+    "rearrangements": [
+      "fusions"
+    ],
+    "or neurotrophic tyrosine receptor kinase": [
+      "ntrk"
+    ],
+    "detection is reliable by in situ hybridisation": [
+      "ish"
+    ],
+    "-deoxy-d-glucose": [
+      "fdg"
+    ],
+    "tumour-node-metastasis": [
+      "tnm"
+    ],
+    "over platinum-based doublet chemotherapy": [
+      "cht"
+    ],
+    "phase iib randomised controlled trial": [
+      "rct"
+    ],
+    "demonstrating a superior median pfs": [
+      "mpfs"
+    ],
+    "m-positive resistant disease": [
+      "occurring in approximately half of the patients"
+    ],
+    "occurring in approximately half of the patients": [
+      "m-positive resistant disease"
+    ],
+    "and alesia": [
+      "asia"
+    ],
+    "entrectinib received food and drug administration": [
+      "fda"
+    ],
+    "the median duration of response": [
+      "dor",
+      "mdor"
+    ],
+    "deruxtecan": [
+      "fda approved"
+    ],
+    "fda approved": [
+      "deruxtecan"
+    ],
+    "the kirsten rat sarcoma virus": [
+      "kras"
+    ],
+    "in particular with the use of modern technologies": [
+      "robotic systems"
+    ],
+    "may benefit from lat": [
+      "high-dose rt or surgery"
+    ],
+    "jennifer lamarre and guy atchison": [
+      "esmo guidelines staff"
+    ],
+    "esmo medical affairs advisor": [
+      "and dr svetlana jezdic"
+    ],
+    "asian thoracic oncology research group": [
+      "atorg"
+    ],
+    "chinese lung cancer research foundation limited": [
+      "clcrf"
+    ],
+    "research to practice": [
+      "rtp"
+    ],
+    "s de clinique": [
+      "asmac"
+    ],
+    "-rearranged advanced non-small-cell lung cancer": [
+      "nsclc"
+    ],
+    "consolidative stereotactic ablative radiotherapy": [
+      "sabr"
+    ],
+    "- the neurotrophic receptor tyrosine kinase": [
+      "ntrk"
+    ],
+    "the japanese society of medical oncology": [
+      "jsmo"
+    ],
+    "the philippine society of medical oncology": [
+      "psmo"
+    ],
+    "the singapore society of oncology": [
+      "sso"
+    ],
+    "and the thai society of clinical oncology": [
+      "tsco"
+    ],
+    "only two of the six expert members from the ksmo": [
+      "tmk and hrk"
+    ],
+    "what is the role of liquid biopsy": [
+      "cfdna"
+    ],
+    "reported improved progression-free survival": [
+      "pfs"
+    ],
+    "stage iv metastatic non-small-cell lung cancer": [
+      "mnsclc"
+    ],
+    "egfr mutation": [
+      "classical activating mutations"
+    ],
+    "classical activating mutations": [
+      "egfr mutation"
+    ],
+    "- local treatment": [
+      "surgery or rt"
+    ],
+    "- objective response rate": [
+      "orr"
+    ],
+    "- duration of response": [
+      "dor"
+    ],
+    "treatment-related adverse events": [
+      "traes"
+    ],
+    "what are the treatment-related adverse events": [
+      "traes"
+    ],
+    "ishmo\n\nthe jaminan kesehatan nasional": [
+      "jkn"
+    ],
+    "program": [
+      "pap"
+    ],
+    "social security and government officer": [
+      "csmbs"
+    ],
+    "in the second-line setting": [
+      "and atezolizumab"
+    ],
+    "second-line with reimbursement through the csmbs": [
+      "erlotinib and osimertinib"
+    ],
+    "and the alk inhibitors ceritinib and brigatinib": [
+      "first-line"
+    ],
+    "tmk": [
+      "author"
+    ],
+    "author": [
+      "jchy",
+      "msi",
+      "tmk",
+      "ddwl",
+      "cew",
+      "sak",
+      "hrk"
+    ],
+    "hrk": [
+      "author"
+    ],
+    "sak": [
+      "author"
+    ],
+    "thoracic oncology research group": [
+      "torg"
+    ],
+    "ddwl": [
+      "author"
+    ],
+    "msi": [
+      "author"
+    ],
+    "jchy": [
+      "author"
+    ],
+    "cew": [
+      "author"
+    ],
+    "non-renumerated": [
+      "product samples"
+    ],
+    "and philippine society of medical oncology": [
+      "psmo"
+    ],
+    "malaysian oncological society": [
+      "mos"
+    ],
+    "medical guideline document - esmo open references": [
+      "continued"
+    ],
+    "mo encorafenib plus binimetinib in patients": [
+      "pts"
+    ],
+    "e-mutant advanced non-small cell lung cancer": [
+      "nsclc"
+    ],
+    "and the european medicines agency": [
+      "ema"
+    ],
+    "with or without prior adjuvant chemotherapy": [
+      "cht"
+    ],
+    "the median was not reached": [
+      "ne-ne"
+    ],
+    "leads to increased dfs versus best supportive care": [
+      "bsc"
+    ],
+    "expression": [
+      "for unresectable nsclc",
+      "for completely resected nsclc"
+    ],
+    "for unresectable nsclc": [
+      "expression"
+    ],
+    "for completely resected nsclc": [
+      "expression"
+    ],
+    "only in adenocarcinoma tumours": [
+      "or docetaxel or pemetrexed"
+    ],
+    "the immune strategy in the": [
+      "neo"
+    ],
+    "resection and after": [
+      "neo"
+    ],
+    "postoperative radiotherapy": [
+      "port"
+    ],
+    "had undergone positron emission tomography": [
+      "pet"
+    ],
+    "disease-free survival": [
+      "dfs"
+    ],
+    "- chemotherapy and radiotherapy": [
+      "cht and rt"
+    ],
+    "cht and rt": [
+      "- chemotherapy and radiotherapy"
+    ],
+    "control": [
+      "median"
+    ],
+    "median": [
+      "control"
+    ],
+    "approval was based on all patient data": [
+      "including stage ib"
+    ],
+    "as per the ema-approved indication": [
+      "on tumour cells"
+    ],
+    "osimertinib as adjuvant therapy in patients": [
+      "pts"
+    ],
+    "with stage ib-iiia egfr mutation positive": [
+      "egfrm"
+    ],
+    "platinum-doublet chemotherapy": [
+      "chemo"
+    ],
+    "for resectable": [
+      "ib-iiia"
+    ],
+    "comparing post-operative conformal radiotherapy": [
+      "port"
+    ],
+    "unresectable non-small-cell lung cancer": [
+      "pacific"
+    ]
+  },
+  "abbreviations": {
+    "esmo": [
+      "european\nsociety of medical oncology",
+      "the following european society for medical oncology",
+      "european society of medical oncology",
+      "european society for medical oncology",
+      "living guideline\n\nthe following european society for medical oncology",
+      "european society for medical\noncology",
+      "european society for\nmedical oncology",
+      "the european society for medical oncology",
+      "the most recent european society for medical oncology"
+    ],
+    "asco": [
+      "american society of clinical\noncology",
+      "american society of clinical\n\noncology",
+      "american society of clinical oncology",
+      "american\nsociety of clinical oncology",
+      "this american society of clinical oncology",
+      "journal of clinical oncology",
+      "the clinical practice guidelines published herein are provided by the american society of clinical oncology inc"
+    ],
+    "aiom": [
+      "italian association\nof medical oncology",
+      "italian association of medical oncology",
+      "the italian association of medical oncology"
+    ],
+    "nccn": [
+      "american cancer centers",
+      "national comprehensive cancer network"
+    ],
+    "glides": [
+      "guidelines into decision\nsupport",
+      "guidelines into decision support",
+      "ecision support"
+    ],
+    "glc": [
+      "guidelines committee"
+    ],
+    "mcbs": [
+      "magnitude of clinical benefit score",
+      "magnitude\nof clinical benefit score",
+      "magnitude of clinical benefit scale"
+    ],
+    "ema": [
+      "european medicines\nagency",
+      "european medicines agency"
+    ],
+    "sclc": [
+      "clinical practice guidelines on small cell lung cancer",
+      "small cell lung cancer",
+      "what is the treatment algorithm for patients with small cell lung cancer",
+      "clinical practice guidelines on small cell lung\ncancer",
+      "what are the recommended treatment options for patients with relapsed small cell lung cancer"
+    ],
+    "cco": [
+      "cancer care ontario"
+    ],
+    "astro": [
+      "executive summary of an american society for radiation oncology",
+      "executive summary of an american society for\nradiation oncology"
+    ],
+    "inst": [
       "merck",
-      "summit therapeutics",
-      "turning point therapeutics",
+      "trizell",
+      "regeneron",
+      "lilly",
+      "heart therapeutics",
+      "elevation oncology",
       "amgen",
       "janssen oncology",
+      "verastem",
+      "myers squibb",
+      "black diamond therapeutics",
+      "zeneca",
+      "janssen",
+      "guardant health",
       "palobiofarma",
-      "regeneron",
-      "kline canada",
-      "forward",
-      "novartis",
-      "mirati therapeutics",
-      "genomics",
-      "sutro biopharma",
-      "immune",
       "constellation pharmaceuticals",
-      "merck serono",
-      "puma biotechnology",
+      "immune",
+      "blueprint medicines",
+      "nuvation bio",
+      "pfizer",
+      "therapeutics",
+      "mirati therapeutics",
+      "revolution medicines",
+      "dohme",
+      "summit therapeutics",
+      "harpoon therapeutics",
+      "macrogenics",
+      "kline canada",
+      "jazz pharmaceuticals",
       "kline",
-      "takeda",
       "genentech",
-      "inhibrx",
-      "verastem",
-      "harpoon therapeutics",
+      "takeda",
       "astra zeneca",
+      "genomics",
       "cullinan oncology",
+      "zeneca canada",
+      "bristol myers\nsquibb",
+      "dizal\npharma",
+      "puma biotechnology",
+      "advaxis",
+      "novartis",
+      "vivace therapeutics",
+      "turning point therapeutics",
+      "astex pharmaceuticals",
+      "merck serono",
+      "exelixis",
+      "bayer",
+      "dizal pharma",
+      "inhibrx",
+      "calithera biosciences",
+      "polaris",
+      "arcus biosciences",
+      "black diamond\ntherapeutics",
+      "boehringer ingelheim",
+      "sutro biopharma",
+      "bristol myers squibb",
+      "forward",
       "roche",
-      "heart therapeutics",
-      "elevation oncology"
+      "pharmaceuticals",
+      "bristol myers squibb foundation"
     ],
     "ct": [
+      "the use of computed tomography",
       "computed tomography",
       "the use of\ncomputed tomography",
       "clinicians should use a diagnostic chest computed tomography"
@@ -2995,18 +3796,23 @@
       "stereotactic body radiotherapy"
     ],
     "cap": [
-      "pathologists"
+      "pathologists",
+      "college of american pathologists"
     ],
     "iaslc": [
+      "pathology committee chair for international association for the study of lung cancer",
+      "study of lung cancer",
       "the\ninternational association for the study of lung cancer",
-      "international association for the\nstudy of lung cancer",
-      "international association for\nthe study of lung cancer",
       "pathology committee chair\nfor international association for the study of lung cancer",
-      "study of lung cancer",
-      "international association for the\n\nstudy of lung cancer"
+      "international association for the\nstudy of lung cancer",
+      "international association for the study of lung cancer",
+      "international association for the\n\nstudy of lung cancer",
+      "the international association for the study of lung cancer",
+      "international association for\nthe study of lung cancer"
     ],
     "amp": [
-      "association\nfor molecular pathology"
+      "association\nfor molecular pathology",
+      "association for molecular pathology"
     ],
     "ihc": [
       "immunohistochemistry"
@@ -3018,8 +3824,11 @@
       "although the results from the mesothelioma and radical surgery"
     ],
     "os": [
+      "the median\noverall survival",
+      "median overall survival",
       "overall survival",
-      "the median\noverall survival"
+      "the median overall survival",
+      "the only data published thus far pertain to the dual primary end points of overall survival"
     ],
     "elsevier": [
       "clinical lung cancer"
@@ -3028,21 +3837,27 @@
       "one randomized controlled trial"
     ],
     "ps": [
-      "eastern cooperative oncology group performance\nstatus"
+      "eastern cooperative oncology group performance\nstatus",
+      "eastern cooperative oncology group performance status"
     ],
     "orr": [
-      "reuss et al\n\n\n\nrate",
-      "is result in a lower overall response\nrate"
+      "is result in a lower overall response\nrate",
+      "objective response rate",
+      "is result in a lower overall response rate",
+      "reuss et al\n\n\n\nrate"
     ],
     "pci": [
-      "prophylactic cranial irradiation"
+      "prophylactic cranial irradiation",
+      "what is the role of prophylactic cranial irradiation"
     ],
     "fda": [
-      "osimertinib is approved by both the united states food and\ndrug administration",
+      "entrectinib received food and\ndrug administration",
+      "entrectinib received food and drug administration",
+      "osimertinib is approved by both the united states food and drug administration",
       "food and drug administration",
-      "these results led to the food\n\nand drug administration",
+      "osimertinib is approved by both the united states food and\ndrug administration",
       "united states food and drug administration",
-      "entrectinib received food and\ndrug administration"
+      "these results led to the food\n\nand drug administration"
     ],
     "crs": [
       "cytokine release syndrome"
@@ -3051,39 +3866,44 @@
       "department of surgical sciences"
     ],
     "who": [
-      "global",
-      "the recent world health organization",
-      "world health organization",
       "the latest world health organization",
-      "global statistics"
+      "world health organization",
+      "global statistics",
+      "global",
+      "the recent world health organization"
     ],
     "lc": [
+      "these guidelines are restricted to lung carcinoid",
       "these\nguidelines are restricted to lung carcinoid"
     ],
     "seer": [
-      "end results",
-      "epidemiology and end results"
+      "epidemiology and end results",
+      "end results"
     ],
     "uicc": [
       "edition of the union for\ninternational cancer control",
-      "union for\ninternational cancer control",
+      "union for international cancer control",
       "union for international\ncancer control",
-      "union for international cancer control"
+      "edition of the union for international cancer control",
+      "union for\ninternational cancer control"
     ],
     "gep": [
-      "based on\napproval and recommendations in gastroenteropancreatic"
+      "based on\napproval and recommendations in gastroenteropancreatic",
+      "based on approval and recommendations in gastroenteropancreatic"
     ],
     "pth": [
       "annals of oncology\n\n\n\nparathyroid hormone"
     ],
     "rfa": [
-      "for these patients radiofrequency ablation",
-      "palliative surgery\nor radiofrequency ablation"
+      "palliative surgery\nor radiofrequency ablation",
+      "palliative surgery or radiofrequency ablation",
+      "for these patients radiofrequency ablation"
     ],
     "recist": [
-      "cs with response evaluation criteria\nin solid tumours",
+      "cs with response evaluation criteria in solid tumours",
       "measurements and response assessment should follow\nresponse evaluation criteria in solid tumours",
-      "measurements and response assessment should follow response evaluation criteria in solid tumours"
+      "measurements and response assessment should follow response evaluation criteria in solid tumours",
+      "cs with response evaluation criteria\nin solid tumours"
     ],
     "gemox": [
       "oxaliplatin combined with gemcitabine"
@@ -3092,11 +3912,12 @@
       "lanreotide autogel"
     ],
     "chuv": [
-      "centre hospitalier universitaire\nvaudois",
-      "centre hospitalier universitaire vaudois"
+      "centre hospitalier universitaire vaudois",
+      "centre hospitalier universitaire\nvaudois"
     ],
     "nlst": [
       "the much larger national lung cancer screening trial",
+      "national cancer institute announced the results of the national lung cancer screening trial",
       "national cancer institute\nannounced the results of the national lung cancer screening\ntrial"
     ],
     "bts": [
@@ -3106,13 +3927,15 @@
       "the latter recommend a lesser reliance on positron emission tomography"
     ],
     "nice": [
+      "national institute for health and care excellence",
       "national institute for health and care\nexcellence"
     ],
     "accp": [
       "american college of chest physicians"
     ],
     "rcri": [
-      "evaluation of the cardiac risk assessment for lung resections\nby the recalibrated thoracic revised cardiac risk index"
+      "evaluation of the cardiac risk assessment for lung resections\nby the recalibrated thoracic revised cardiac risk index",
+      "evaluation of the cardiac risk assessment for lung resections by the recalibrated thoracic revised cardiac risk index"
     ],
     "lcsg": [
       "based on the lung cancer study group"
@@ -3122,7 +3945,8 @@
     ],
     "rtog": [
       "data from a completed prospective\nradiation therapy oncology group",
-      "radiation therapy oncology group"
+      "radiation therapy oncology group",
+      "data from a completed prospective radiation therapy oncology group"
     ],
     "esge": [
       "european society of gastrointestinal endoscopy"
@@ -3131,18 +3955,20 @@
       "european respiratory society"
     ],
     "ests": [
-      "european society of thoracic surgeons",
-      "european\nsociety of thoracic surgeons"
+      "european association of thoracic surgeons",
+      "european\nsociety of thoracic surgeons",
+      "european society of thoracic surgeons"
     ],
     "thoracoscore": [
-      "the thoracic surgery scoring\nsystem",
-      "the thoracic surgery scoring system"
+      "the thoracic surgery scoring system",
+      "the thoracic surgery scoring\nsystem"
     ],
     "pulmonology": [
-      "respiratory oncology",
-      "respiratory oncology unit"
+      "respiratory oncology unit",
+      "respiratory oncology"
     ],
     "acs": [
+      "lung cancer screening guidelines published by the american cancer society",
       "lung cancer screening guidelines published by the\namerican cancer society"
     ],
     "ialt": [
@@ -3152,27 +3978,35 @@
       "adjuvant navelbine international trialist association"
     ],
     "sabr": [
-      "radiographic changes after lung stereotactic\nablative radiotherapy"
+      "what are the indications and recommendations for salvage surgery after stereotactic ablative radiotherapy",
+      "radiographic changes after lung stereotactic ablative radiotherapy",
+      "what are the outcomes comparing stereotactic ablative radiotherapy",
+      "radiographic changes after lung stereotactic\nablative radiotherapy",
+      "consolidative stereotactic ablative radiotherapy"
     ],
     "vumc": [
+      "vrije\nuniversity medical centre",
       "university medical centre",
-      "vrije\nuniversity medical centre"
+      "vrije university medical centre"
     ],
     "ub": [
       "bemeneed"
     ],
     "bms": [
-      "bristol myers\nsquibb",
       "myers\nsquibb",
+      "bristol myers\nsquibb",
+      "bristol\nmyers squibb",
       "bristol myers squibb",
-      "bristol\nmyers squibb"
+      "myers squibb"
     ],
     "msd": [
       "dohme"
     ],
     "eortc": [
-      "treatment of cancer",
+      "chair of the european organisation for research and treatment of cancer",
       "chair of the european\norganisation for research and treatment of cancer",
+      "european organisation for research and treatment of cancer",
+      "treatment of cancer",
       "european\norganisation for research and treatment of cancer"
     ],
     "cpg": [
@@ -3187,6 +4021,7 @@
       "positive anaplastic lymphoma kinase"
     ],
     "ish": [
+      "detection is reliable by in situ hybridisation",
       "detection is reliable by\nin situ hybridisation"
     ],
     "cns": [
@@ -3206,6 +4041,7 @@
       "interstitial lung disease"
     ],
     "kras": [
+      "the kirsten rat sarcoma virus",
       "the\nkirsten rat sarcoma virus"
     ],
     "lat": [
@@ -3218,19 +4054,21 @@
       "kline"
     ],
     "nvalt": [
-      "lung cancer group and past secretary and current\nchair of the nederlandse vereniging van artsen voor longziekten en tuberculose",
-      "nederlandse vereniging van artsen voor longziekten en tuberculose"
+      "nederlandse vereniging van artsen voor longziekten en tuberculose",
+      "lung cancer group and past secretary and current\nchair of the nederlandse vereniging van artsen voor longziekten en tuberculose"
     ],
     "atorg": [
-      "asian\nthoracic oncology research group"
+      "asian\nthoracic oncology research group",
+      "asian thoracic oncology research group"
     ],
     "clcrf": [
-      "chinese lung\ncancer research foundation limited"
+      "chinese lung\ncancer research foundation limited",
+      "chinese lung cancer research foundation limited"
     ],
     "csco": [
+      "chinese\nsociety of clinical oncology",
       "chinese society of clinical oncology",
-      "china",
-      "chinese\nsociety of clinical oncology"
+      "china"
     ],
     "hkcf": [
       "hong kong cancer fund"
@@ -3245,14 +4083,17 @@
       "partnerships in international medical education"
     ],
     "rtp": [
-      "research\nto practice"
+      "research\nto practice",
+      "research to practice"
     ],
     "samo": [
-      "president of swiss\nacademy of multidisciplinary oncology"
+      "president of swiss\nacademy of multidisciplinary oncology",
+      "president of swiss academy of multidisciplinary oncology"
     ],
     "sakk": [
+      "research",
       "president of lung group for swiss group for clinical cancer\nresearch",
-      "research"
+      "president of lung group for swiss group for clinical cancer research"
     ],
     "etop": [
       "european thoracic oncology platform"
@@ -3261,6 +4102,7 @@
       "international breast cancer study group"
     ],
     "aacr": [
+      "partners member of american association of cancer research",
       "partners member\nof american association of cancer research"
     ],
     "asmac": [
@@ -3270,52 +4112,58 @@
       "cancers"
     ],
     "chmp": [
-      "products for human use",
-      "summary of opinion"
+      "summary of opinion",
+      "committee for medicinal products for human use",
+      "products for human use"
     ],
     "paga": [
       "asian adapted"
     ],
     "ishmo": [
       "indonesia",
-      "indonesian society\nof hematology and medical oncology"
+      "indonesian society\nof hematology and medical oncology",
+      "indonesian society of hematology and medical oncology"
     ],
     "jsmo": [
-      "japan",
-      "japanese society of medical oncology"
+      "japanese society of medical oncology",
+      "japan"
     ],
     "ksmo": [
       "korea",
       "korean society for medical oncology"
     ],
     "mos": [
-      "malaysia",
-      "malaysian oncological society"
+      "malaysian oncological society",
+      "malaysia"
     ],
     "psmo": [
       "philippine society of\nmedical oncology",
+      "philippine society of medical\noncology",
       "philippines",
-      "philippine society of medical\noncology"
+      "philippine society of medical oncology"
     ],
     "sso": [
-      "singapore",
-      "singapore society of\noncology"
+      "singapore society of\noncology",
+      "singapore society of oncology",
+      "singapore"
     ],
     "tos": [
       "taiwan oncology society",
       "taiwan"
     ],
     "tsco": [
-      "thailand",
-      "thai society of clinical oncology"
+      "thai society of clinical oncology",
+      "thailand"
     ],
     "ismpo": [
+      "indian society of medical and paediatric oncology",
       "indian\nsociety of medical and paediatric oncology"
     ],
     "nsmpa": [
       "national medical products\nadministration"
     ],
     "nmpa": [
+      "chinese national medical products administration",
       "chinese national\nmedical products administration"
     ],
     "jkn": [
@@ -3323,18 +4171,22 @@
     ],
     "fornas": [
       "na\ntional drug formulary",
-      "national standard of\nmedication list"
+      "national standard of medication list",
+      "national standard of\nmedication list",
+      "national drug formulary"
     ],
     "pap": [
       "open\n\n\n\nprogram"
     ],
     "pdma": [
-      "it may take\nfrom several months to years for the pharmaceuticals and\nmedical devices agency"
+      "it may take\nfrom several months to years for the pharmaceuticals and\nmedical devices agency",
+      "it may take from several months to years for the pharmaceuticals and medical devices agency"
     ],
     "nhi": [
       "national health insurance"
     ],
     "torg": [
+      "thoracic oncology research group",
       "thoracic oncology research\ngroup"
     ],
     "wjog": [
@@ -3344,7 +4196,8 @@
       "trial steering committee"
     ],
     "idmc": [
-      "committee"
+      "committee",
+      "independent data monitoring committee"
     ],
     "ukiog": [
       "ireland oesophagogastric group"
@@ -3411,10 +4264,71 @@
       "advanced"
     ],
     "nsclc": [
-      "small cell lung cancer"
+      "small cell lung cancer",
+      "cell lung cancer"
     ],
     "uk": [
       "guidelines"
+    ],
+    "scc": [
+      "squamous cell carcinoma"
+    ],
+    "hr": [
+      "hazard ratio"
+    ],
+    "pfs": [
+      "free survival"
+    ],
+    "all-cause": [
+      "adverse events"
+    ],
+    "tc": [
+      "typical carcinoid"
+    ],
+    "ac": [
+      "atypical carcinoid"
+    ],
+    "prrt": [
+      "what is the role of peptide receptor radionuclide therapy"
+    ],
+    "dipnech": [
+      "diffuse idiopathic pulmonary neuroendocrine cell hyperplasia"
+    ],
+    "port": [
+      "postoperative radiotherapy",
+      "radiotherapy",
+      "what is the current evidence and recommendation for postoperative radiotherapy",
+      "what are the outcomes and recommendations for postoperative radiotherapy"
+    ],
+    "i-v": [
+      "classification system showing five levels of evidence"
+    ],
+    "vats": [
+      "assisted thoracic surgery"
+    ],
+    "maastro": [
+      "department of radiation oncology"
+    ],
+    "pi": [
+      "institutional funding as local principal investigator"
+    ],
+    "ipsos": [
+      "roche and                                regimen"
+    ],
+    "rt": [
+      "the addition of radiotherapy"
+    ],
+    "ntrk": [
+      "the neurotrophic receptor tyrosine kinase"
+    ],
+    "dor": [
+      "duration of response"
+    ],
+    "continued": [
+      "open references"
+    ],
+    "dfs": [
+      "free survival"
     ]
   }
 }

data/vector_store/index.faiss

@@ -1,3 +1,3 @@
 version https://git-lfs.github.com/spec/v1
-oid sha256:824156db2ada7613098cc7c9a8c27d66b33553885146fb6f66ab450ddc5d95cb
-size 8248365
+oid sha256:63b37a30452df70831044506a22d6abe7f75ccff6000346d96eb5e50f3a5cbc4
+size 13099053

data/vector_store/index.pkl

@@ -1,3 +1,3 @@
 version https://git-lfs.github.com/spec/v1
-oid sha256:33526894d8ea0561a0bfa56d6f00433a7cc404935481583644abdd2dc3a67be6
-size 4020643
+oid sha256:937c7bf3a01f263a0b0feacbf258ba952fe41d339e6c9e81b15cdf9b3156754b
+size 5279713

logs/app.log

@@ -9084,3 +9084,181 @@ ImportError: cannot import name 'store_user_question' from 'core.tools' (d:\Work
 2025-11-10 15:10:03,545 - AgenticMedicalRAG - INFO - Background validation completed - Interaction ID: 10
 2025-11-10 15:10:03,545 - AgenticMedicalRAG - INFO - Validation scores - Overall: 97/100, Accuracy: 95/100, Coherence: 100/100, Relevance: 100/100
 2025-11-10 15:10:03,545 - AgenticMedicalRAG - INFO - Successfully processed user input: what questions i asked?...
+2025-11-16 13:04:27,063 - AgenticMedicalRAG - INFO - Configuration validation completed
+2025-11-16 13:04:27,911 - AgenticMedicalRAG - INFO - Loaded 877 learned synonyms from cache
+2025-11-16 13:04:28,088 - AgenticMedicalRAG - INFO - 🚀 Starting background initialization...
+2025-11-16 13:04:28,089 - AgenticMedicalRAG - INFO - 🔄 Background Init: Starting background initialization... (0%)
+2025-11-16 13:04:28,089 - AgenticMedicalRAG - INFO - 🔄 Background Init: Loading embedding model... (10%)
+2025-11-16 13:04:28,090 - AgenticMedicalRAG - INFO - Loading embedding model (first time)...
+2025-11-16 13:04:34,112 - AgenticMedicalRAG - INFO - Embedding model loaded successfully
+2025-11-16 13:04:34,112 - AgenticMedicalRAG - INFO - 🔄 Background Init: Embedding model loaded successfully (40%)
+2025-11-16 13:04:34,112 - AgenticMedicalRAG - INFO - 🔄 Background Init: Initializing retrievers and loading chunks... (50%)
+2025-11-16 13:04:34,112 - AgenticMedicalRAG - INFO - 🔄 Initializing retrievers (first time use)...
+2025-11-16 13:04:34,113 - AgenticMedicalRAG - INFO - 🔄 Processing new data and updating vector store if needed...
+2025-11-16 13:04:34,114 - AgenticMedicalRAG - INFO - ℹ️ No vector store found; attempting creation from cached chunks...
+2025-11-16 13:15:41,734 - AgenticMedicalRAG - INFO - ✅ Vector store created from cached chunks
+2025-11-16 13:15:41,734 - AgenticMedicalRAG - INFO - 📦 Loading chunks cache for BM25 retriever...
+2025-11-16 13:15:41,975 - AgenticMedicalRAG - INFO - 🔍 Creating vector retriever...
+2025-11-16 13:15:41,976 - AgenticMedicalRAG - INFO - 📝 Creating BM25 retriever...
+2025-11-16 13:15:42,172 - AgenticMedicalRAG - INFO - 🔄 Creating hybrid retriever...
+2025-11-16 13:15:42,173 - AgenticMedicalRAG - INFO - ✅ Retrievers initialized successfully.
+2025-11-16 13:15:42,174 - AgenticMedicalRAG - INFO - 🔄 Background Init: Retrievers initialized successfully (90%)
+2025-11-16 13:15:42,175 - AgenticMedicalRAG - INFO - 🔄 Background Init: Learning medical terminology from corpus... (92%)
+2025-11-16 13:15:44,409 - AgenticMedicalRAG - INFO - Saved learned terms to cache
+2025-11-16 13:15:44,409 - AgenticMedicalRAG - INFO - Learned medical terminology from 1000 documents
+2025-11-16 13:15:44,409 - AgenticMedicalRAG - INFO - 🔄 Background Init: Warming up LLM... (97%)
+2025-11-16 13:15:44,410 - AgenticMedicalRAG - INFO - Initializing LLM (first time)...
+2025-11-16 13:15:44,971 - AgenticMedicalRAG - INFO - LLM initialized successfully
+2025-11-16 13:15:44,971 - AgenticMedicalRAG - INFO - 🔄 Background Init: All components initialized successfully (100%)
+2025-11-16 13:15:44,971 - AgenticMedicalRAG - INFO - ✅ Background initialization completed successfully
+2025-11-16 13:27:05,041 - AgenticMedicalRAG - INFO - Processing user input (attempt 1): Give me the options for first line treatment for N...
+2025-11-16 13:27:07,590 - AgenticMedicalRAG - INFO - No specific provider - querying each provider separately for balanced results
+2025-11-16 13:27:07,590 - AgenticMedicalRAG - INFO - Querying provider: NCCN
+2025-11-16 13:27:07,644 - AgenticMedicalRAG - INFO - Hybrid search returned 0 unique documents (query expansion: False)
+2025-11-16 13:27:07,644 - AgenticMedicalRAG - INFO - Querying provider: ASCO
+2025-11-16 13:27:07,692 - AgenticMedicalRAG - INFO - Hybrid search returned 1 unique documents (query expansion: False)
+2025-11-16 13:27:07,714 - AgenticMedicalRAG - INFO - Enriched 1 documents with surrounding context pages
+2025-11-16 13:27:07,715 - AgenticMedicalRAG - INFO - Retrieved 1 documents from ASCO
+2025-11-16 13:27:07,715 - AgenticMedicalRAG - INFO - Querying provider: ESMO
+2025-11-16 13:27:07,762 - AgenticMedicalRAG - INFO - Hybrid search returned 6 unique documents (query expansion: False)
+2025-11-16 13:27:07,765 - AgenticMedicalRAG - INFO - Enriched 1 documents with surrounding context pages
+2025-11-16 13:27:07,765 - AgenticMedicalRAG - INFO - Retrieved 6 documents from ESMO
+2025-11-16 13:27:07,765 - AgenticMedicalRAG - INFO - Querying provider: NICE
+2025-11-16 13:27:07,807 - AgenticMedicalRAG - INFO - Hybrid search returned 5 unique documents (query expansion: False)
+2025-11-16 13:27:07,809 - AgenticMedicalRAG - INFO - Enriched 1 documents with surrounding context pages
+2025-11-16 13:27:07,809 - AgenticMedicalRAG - INFO - Retrieved 5 documents from NICE
+2025-11-16 13:27:07,809 - AgenticMedicalRAG - INFO - Querying provider: Manus
+2025-11-16 13:27:07,850 - AgenticMedicalRAG - INFO - Hybrid search returned 0 unique documents (query expansion: False)
+2025-11-16 13:27:19,740 - AgenticMedicalRAG - INFO - Successfully processed user input: Give me the options for first line treatment for N...
+2025-11-16 13:27:19,740 - AgenticMedicalRAG - INFO - Performing background validation...
+2025-11-16 13:27:20,103 - AgenticMedicalRAG - INFO - Medical answer validator initialized successfully
+2025-11-16 13:27:20,103 - AgenticMedicalRAG - INFO - GitHub token configured: ghp_KWH...dnCc
+2025-11-16 13:27:20,104 - AgenticMedicalRAG - INFO - GitHub storage initialized for MoazEldsouky/cloud-data-store
+2025-11-16 13:27:21,444 - AgenticMedicalRAG - INFO - Found 19 existing evaluations in GitHub
+2025-11-16 13:27:21,445 - AgenticMedicalRAG - INFO - Next interaction ID will be: 20
+2025-11-16 13:27:21,445 - AgenticMedicalRAG - INFO - Starting validation for interaction 20
+2025-11-16 13:27:31,426 - AgenticMedicalRAG - INFO - Attempting to save evaluation with ID: 20
+2025-11-16 13:27:31,427 - AgenticMedicalRAG - INFO - GitHub storage instance obtained, calling save_validation_results...
+2025-11-16 13:27:31,427 - AgenticMedicalRAG - INFO - Attempt 1/3: Loading existing evaluations from GitHub...
+2025-11-16 13:27:32,515 - AgenticMedicalRAG - INFO - Successfully loaded 19 existing evaluations
+2025-11-16 13:27:32,516 - AgenticMedicalRAG - INFO - Adding new evaluation with ID: 20
+2025-11-16 13:27:32,516 - AgenticMedicalRAG - INFO - Appended new evaluation. Total count: 20
+2025-11-16 13:27:33,763 - AgenticMedicalRAG - INFO - Uploading to GitHub: medical_data/evaluation_results.json (size: 770627 bytes)
+2025-11-16 13:27:35,299 - AgenticMedicalRAG - INFO - ✓ Successfully uploaded medical_data/evaluation_results.json to GitHub
+2025-11-16 13:27:35,300 - AgenticMedicalRAG - INFO - ✓ Successfully saved evaluation 20. Total evaluations now: 20
+2025-11-16 13:27:35,301 - AgenticMedicalRAG - INFO - ✓ Evaluation saved to GitHub successfully with ID: 20
+2025-11-16 13:27:35,301 - AgenticMedicalRAG - INFO - Background validation completed - Interaction ID: 20
+2025-11-16 13:27:35,301 - AgenticMedicalRAG - INFO - Validation scores - Overall: 90/100, Accuracy: 95/100, Coherence: 90/100, Relevance: 88/100
+2025-11-16 13:49:31,769 - AgenticMedicalRAG - INFO - Configuration validation completed
+2025-11-16 13:49:33,262 - AgenticMedicalRAG - INFO - Loaded 1085 learned synonyms from cache
+2025-11-16 13:49:33,722 - AgenticMedicalRAG - INFO - 🚀 Starting background initialization...
+2025-11-16 13:49:33,722 - AgenticMedicalRAG - INFO - 🔄 Background Init: Starting background initialization... (0%)
+2025-11-16 13:49:33,723 - AgenticMedicalRAG - INFO - 🔄 Background Init: Loading embedding model... (10%)
+2025-11-16 13:49:33,723 - AgenticMedicalRAG - INFO - Loading embedding model (first time)...
+2025-11-16 13:49:43,878 - AgenticMedicalRAG - INFO - Embedding model loaded successfully
+2025-11-16 13:49:43,879 - AgenticMedicalRAG - INFO - 🔄 Background Init: Embedding model loaded successfully (40%)
+2025-11-16 13:49:43,879 - AgenticMedicalRAG - INFO - 🔄 Background Init: Initializing retrievers and loading chunks... (50%)
+2025-11-16 13:49:43,879 - AgenticMedicalRAG - INFO - 🔄 Initializing retrievers (first time use)...
+2025-11-16 13:49:43,879 - AgenticMedicalRAG - INFO - 🔄 Processing new data and updating vector store if needed...
+2025-11-16 13:49:44,046 - AgenticMedicalRAG - INFO - 📦 Loading chunks cache for BM25 retriever...
+2025-11-16 13:49:44,080 - AgenticMedicalRAG - INFO - 🔍 Creating vector retriever...
+2025-11-16 13:49:44,080 - AgenticMedicalRAG - INFO - 📝 Creating BM25 retriever...
+2025-11-16 13:49:44,795 - AgenticMedicalRAG - INFO - 🔄 Creating hybrid retriever...
+2025-11-16 13:49:44,795 - AgenticMedicalRAG - INFO - ✅ Retrievers initialized successfully.
+2025-11-16 13:49:44,795 - AgenticMedicalRAG - INFO - 🔄 Background Init: Retrievers initialized successfully (90%)
+2025-11-16 13:49:44,796 - AgenticMedicalRAG - INFO - 🔄 Background Init: Learning medical terminology from corpus... (92%)
+2025-11-16 13:49:48,978 - AgenticMedicalRAG - INFO - Saved learned terms to cache
+2025-11-16 13:49:48,978 - AgenticMedicalRAG - INFO - Learned medical terminology from 1000 documents
+2025-11-16 13:49:48,979 - AgenticMedicalRAG - INFO - 🔄 Background Init: Warming up LLM... (97%)
+2025-11-16 13:49:48,979 - AgenticMedicalRAG - INFO - Initializing LLM (first time)...
+2025-11-16 13:49:50,261 - AgenticMedicalRAG - INFO - LLM initialized successfully
+2025-11-16 13:49:50,261 - AgenticMedicalRAG - INFO - 🔄 Background Init: All components initialized successfully (100%)
+2025-11-16 13:49:50,261 - AgenticMedicalRAG - INFO - ✅ Background initialization completed successfully
+2025-11-16 13:49:58,194 - AgenticMedicalRAG - INFO - Processing user input (attempt 1): Give me the options for first line treatment for N...
+2025-11-16 13:50:01,198 - AgenticMedicalRAG - INFO - No specific provider - querying each provider separately for balanced results
+2025-11-16 13:50:01,199 - AgenticMedicalRAG - INFO - Querying provider: NCCN
+2025-11-16 13:50:01,796 - AgenticMedicalRAG - INFO - Hybrid search returned 0 unique documents (query expansion: False)
+2025-11-16 13:50:01,796 - AgenticMedicalRAG - INFO - Querying provider: ASCO
+2025-11-16 13:50:01,867 - AgenticMedicalRAG - INFO - Hybrid search returned 1 unique documents (query expansion: False)
+2025-11-16 13:50:01,908 - AgenticMedicalRAG - INFO - Enriched 1 documents with surrounding context pages
+2025-11-16 13:50:01,909 - AgenticMedicalRAG - INFO - Retrieved 1 documents from ASCO
+2025-11-16 13:50:01,909 - AgenticMedicalRAG - INFO - Querying provider: ESMO
+2025-11-16 13:50:01,980 - AgenticMedicalRAG - INFO - Hybrid search returned 6 unique documents (query expansion: False)
+2025-11-16 13:50:01,983 - AgenticMedicalRAG - INFO - Enriched 1 documents with surrounding context pages
+2025-11-16 13:50:01,983 - AgenticMedicalRAG - INFO - Retrieved 6 documents from ESMO
+2025-11-16 13:50:01,983 - AgenticMedicalRAG - INFO - Querying provider: NICE
+2025-11-16 13:50:02,054 - AgenticMedicalRAG - INFO - Hybrid search returned 5 unique documents (query expansion: False)
+2025-11-16 13:50:02,058 - AgenticMedicalRAG - INFO - Enriched 1 documents with surrounding context pages
+2025-11-16 13:50:02,058 - AgenticMedicalRAG - INFO - Retrieved 5 documents from NICE
+2025-11-16 13:50:02,058 - AgenticMedicalRAG - INFO - Querying provider: Manus
+2025-11-16 13:50:02,128 - AgenticMedicalRAG - INFO - Hybrid search returned 0 unique documents (query expansion: False)
+2025-11-16 13:50:14,034 - AgenticMedicalRAG - INFO - Successfully processed user input: Give me the options for first line treatment for N...
+2025-11-16 13:50:14,034 - AgenticMedicalRAG - INFO - Performing background validation...
+2025-11-16 13:50:14,807 - AgenticMedicalRAG - INFO - Medical answer validator initialized successfully
+2025-11-16 13:50:14,807 - AgenticMedicalRAG - INFO - GitHub token configured: ghp_KWH...dnCc
+2025-11-16 13:50:14,807 - AgenticMedicalRAG - INFO - GitHub storage initialized for MoazEldsouky/cloud-data-store
+2025-11-16 13:50:15,682 - AgenticMedicalRAG - INFO - Found 20 existing evaluations in GitHub
+2025-11-16 13:50:15,683 - AgenticMedicalRAG - INFO - Next interaction ID will be: 21
+2025-11-16 13:50:15,683 - AgenticMedicalRAG - INFO - Starting validation for interaction 21
+2025-11-16 13:50:27,358 - AgenticMedicalRAG - INFO - Attempting to save evaluation with ID: 21
+2025-11-16 13:50:27,358 - AgenticMedicalRAG - INFO - GitHub storage instance obtained, calling save_validation_results...
+2025-11-16 13:50:27,358 - AgenticMedicalRAG - INFO - Attempt 1/3: Loading existing evaluations from GitHub...
+2025-11-16 13:50:28,402 - AgenticMedicalRAG - INFO - Successfully loaded 20 existing evaluations
+2025-11-16 13:50:28,402 - AgenticMedicalRAG - INFO - Adding new evaluation with ID: 21
+2025-11-16 13:50:28,402 - AgenticMedicalRAG - INFO - Appended new evaluation. Total count: 21
+2025-11-16 13:50:29,341 - AgenticMedicalRAG - INFO - Uploading to GitHub: medical_data/evaluation_results.json (size: 798145 bytes)
+2025-11-16 13:50:31,498 - AgenticMedicalRAG - INFO - ✓ Successfully uploaded medical_data/evaluation_results.json to GitHub
+2025-11-16 13:50:31,499 - AgenticMedicalRAG - INFO - ✓ Successfully saved evaluation 21. Total evaluations now: 21
+2025-11-16 13:50:31,500 - AgenticMedicalRAG - INFO - ✓ Evaluation saved to GitHub successfully with ID: 21
+2025-11-16 13:50:31,501 - AgenticMedicalRAG - INFO - Background validation completed - Interaction ID: 21
+2025-11-16 13:50:31,501 - AgenticMedicalRAG - INFO - Validation scores - Overall: 90/100, Accuracy: 95/100, Coherence: 90/100, Relevance: 88/100
+2025-11-16 14:25:55,300 - AgenticMedicalRAG - INFO - Configuration validation completed
+2025-11-16 14:25:56,281 - AgenticMedicalRAG - INFO - Loaded 1085 learned synonyms from cache
+2025-11-16 14:25:56,679 - AgenticMedicalRAG - INFO - 🚀 Starting background initialization...
+2025-11-16 14:25:56,680 - AgenticMedicalRAG - INFO - 🔄 Background Init: Starting background initialization... (0%)
+2025-11-16 14:25:56,680 - AgenticMedicalRAG - INFO - 🔄 Background Init: Loading embedding model... (10%)
+2025-11-16 14:25:56,680 - AgenticMedicalRAG - INFO - Loading embedding model (first time)...
+2025-11-16 14:26:05,152 - AgenticMedicalRAG - INFO - Embedding model loaded successfully
+2025-11-16 14:26:05,152 - AgenticMedicalRAG - INFO - 🔄 Background Init: Embedding model loaded successfully (40%)
+2025-11-16 14:26:05,153 - AgenticMedicalRAG - INFO - 🔄 Background Init: Initializing retrievers and loading chunks... (50%)
+2025-11-16 14:26:05,153 - AgenticMedicalRAG - INFO - 🔄 Initializing retrievers (first time use)...
+2025-11-16 14:26:05,153 - AgenticMedicalRAG - INFO - 🔄 Processing new data and updating vector store if needed...
+2025-11-16 14:26:05,266 - AgenticMedicalRAG - INFO - 📦 Loading chunks cache for BM25 retriever...
+2025-11-16 14:26:05,325 - AgenticMedicalRAG - INFO - 🔍 Creating vector retriever...
+2025-11-16 14:26:05,325 - AgenticMedicalRAG - INFO - 📝 Creating BM25 retriever...
+2025-11-16 14:26:06,073 - AgenticMedicalRAG - INFO - 🔄 Creating hybrid retriever...
+2025-11-16 14:26:06,074 - AgenticMedicalRAG - INFO - ✅ Retrievers initialized successfully.
+2025-11-16 14:26:06,074 - AgenticMedicalRAG - INFO - 🔄 Background Init: Retrievers initialized successfully (90%)
+2025-11-16 14:26:06,074 - AgenticMedicalRAG - INFO - 🔄 Background Init: Learning medical terminology from corpus... (92%)
+2025-11-16 14:26:10,494 - AgenticMedicalRAG - INFO - Saved learned terms to cache
+2025-11-16 14:26:10,494 - AgenticMedicalRAG - INFO - Learned medical terminology from 1000 documents
+2025-11-16 14:26:10,495 - AgenticMedicalRAG - INFO - 🔄 Background Init: Warming up LLM... (97%)
+2025-11-16 14:26:10,495 - AgenticMedicalRAG - INFO - Initializing LLM (first time)...
+2025-11-16 14:26:11,720 - AgenticMedicalRAG - INFO - LLM initialized successfully
+2025-11-16 14:26:11,721 - AgenticMedicalRAG - INFO - 🔄 Background Init: All components initialized successfully (100%)
+2025-11-16 14:26:11,721 - AgenticMedicalRAG - INFO - ✅ Background initialization completed successfully
+2025-11-16 14:31:41,810 - AgenticMedicalRAG - INFO - Configuration validation completed
+2025-11-16 14:31:42,705 - AgenticMedicalRAG - INFO - Loaded 1085 learned synonyms from cache
+2025-11-16 14:31:42,938 - AgenticMedicalRAG - INFO - 🚀 Starting background initialization...
+2025-11-16 14:31:42,939 - AgenticMedicalRAG - INFO - 🔄 Background Init: Starting background initialization... (0%)
+2025-11-16 14:31:42,940 - AgenticMedicalRAG - INFO - 🔄 Background Init: Loading embedding model... (10%)
+2025-11-16 14:31:42,941 - AgenticMedicalRAG - INFO - Loading embedding model (first time)...
+2025-11-16 14:31:50,951 - AgenticMedicalRAG - INFO - Embedding model loaded successfully
+2025-11-16 14:31:50,951 - AgenticMedicalRAG - INFO - 🔄 Background Init: Embedding model loaded successfully (40%)
+2025-11-16 14:31:50,951 - AgenticMedicalRAG - INFO - 🔄 Background Init: Initializing retrievers and loading chunks... (50%)
+2025-11-16 14:31:50,952 - AgenticMedicalRAG - INFO - 🔄 Initializing retrievers (first time use)...
+2025-11-16 14:31:50,952 - AgenticMedicalRAG - INFO - 🔄 Processing new data and updating vector store if needed...
+2025-11-16 14:31:51,017 - AgenticMedicalRAG - INFO - 📦 Loading chunks cache for BM25 retriever...
+2025-11-16 14:31:51,036 - AgenticMedicalRAG - INFO - 🔍 Creating vector retriever...
+2025-11-16 14:31:51,037 - AgenticMedicalRAG - INFO - 📝 Creating BM25 retriever...
+2025-11-16 14:31:51,475 - AgenticMedicalRAG - INFO - 🔄 Creating hybrid retriever...
+2025-11-16 14:31:51,475 - AgenticMedicalRAG - INFO - ✅ Retrievers initialized successfully.
+2025-11-16 14:31:51,475 - AgenticMedicalRAG - INFO - 🔄 Background Init: Retrievers initialized successfully (90%)
+2025-11-16 14:31:51,475 - AgenticMedicalRAG - INFO - 🔄 Background Init: Learning medical terminology from corpus... (92%)
+2025-11-16 14:31:53,736 - AgenticMedicalRAG - INFO - Saved learned terms to cache
+2025-11-16 14:31:53,737 - AgenticMedicalRAG - INFO - Learned medical terminology from 1000 documents
+2025-11-16 14:31:53,737 - AgenticMedicalRAG - INFO - 🔄 Background Init: Warming up LLM... (97%)
+2025-11-16 14:31:53,737 - AgenticMedicalRAG - INFO - Initializing LLM (first time)...
+2025-11-16 14:31:54,318 - AgenticMedicalRAG - INFO - LLM initialized successfully
+2025-11-16 14:31:54,319 - AgenticMedicalRAG - INFO - 🔄 Background Init: All components initialized successfully (100%)
+2025-11-16 14:31:54,319 - AgenticMedicalRAG - INFO - ✅ Background initialization completed successfully

tempCodeRunnerFile.py

@@ -0,0 +1 @@
+access_log